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INTRODUCTION 
 Amniotic fluid forms an aquatic pond inside the amniotic cavity surrounding 
the fetus. 
 
 It provides a protected milieu for the growing fetus, supplying nutrients 
facilitating growth, movement and cushioning the fetus against mechanical and 
biological injury. 
 
 It promotes normal development of fetal lungs and musculoskeletal and gast 
rointestinal systems. It helps to avert compression of umbilical cord and creates a 
physical space for the fetal skeleton to shape normally. It has antibacterial 
properties,and serves as a reservoir of water and nutrients. 
  
The quantity of liquor amnii increases from 25ml at 10 weeks to 400ml at 20 
weeks. The volume increases to about 800 – 1000ml at 28 weeks. Plateaus near 
term and declines to about 400ml at 42 weeks.
1
 
 
 Reduction in the volume of amniotic fluid is called oligohydramnios, 
affecting 3% to 5% of pregnancies. Amniotic fluid index is a tool used for semi 
quantitative measure of amniotic fluid  and is a third trimester technique useful 
8 
after the fundus is above the umbilicus. Amniotic fluid index is a more objective 
and reproducible method of assessment of amniotic fluid volume as it estimates the 
amniotic fluid in four quadrants of the uterus. An AFI of 5-18cm is considered 
normal. 
 
  Phelan
2
 who described Amniotic Fluid Index defined oligohydroamnios as 
AFI less than 5cm.Using amniotic fluid index of less than 5cm the incidence of  
oligohydrmnios was found to be 2.3%  after 34 weeks.oligohydramnios  is 
associated with  increased risk of adverse perinatal outcome.The  umbilical cord  
compression  during labour  is  common with oligohydramnios  which increases 
the risk for caesarean delivery for fetal distress and 5minutes APGAR score less 
than 7. 
 
 Oligohydroamnios in third trimester  is associated with non-reassuring fetal 
heart pattern, increased labour induction, meconium aspiration syndrome, still birth 
and neonatal death – casey & co workers 2004.3 
 
 Sherer etal in 1990
4
  
 
confirmed a significant increase in amniotic fluid 
volume after oral or intravenous hydration in women with oligohydramnios. This 
9 
present study is undertaken to assess the effect of intra venous maternal hydration 
therapy in third trimester oligohydramnios and to assess the perinatal outcome. 
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AIM OF THE STUDY 
1. To study the impact of intravenous maternal hydration therapy on amniotic 
fluid index in cases with oligohydramnios in third trimester. 
 
2. To study the perinatal outcome in these patients. 
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 REVIEW OF LITERATURE  
 Amniotic fluid is  normally the clear  fluid  that collects  within  the amniotic 
cavity. This fluid provides several important benefits.Amniotic fluid has a  number 
of  important roles in embryo/fetal development like, 
1.  Permitting   fetal movement and the development of the musculo skeletal 
system. 
2. Swallowing of amniotic fluid enhances the growth and development of 
gastrointestinal system. 
3. Amniotic fluid  volume  maintains amniotic fluid pressure there by reducing 
the loss of lung liquid an essential component to pulmonary 
development.(Nicolini,1989)  
4. The ingestion   fluid provides   some   fetal   nutrition  and    essential 
nutrients. 
5. Amnioticfluid   protects the fetus from external trauma. 
6. Its constant temperature   helps  to maintain the embryo's  body temperature. 
7. Its bacteriostatic  properties reduce the potential for infection. 
8. Protects the umbilical cord from compression. 
 
 
 
12 
The Amnion; 
The amnion is first identifiable about 7
th
 or 8
th
  day of embryo development. 
To start with a minute vesicle, amnion develops into a small sac that covers the 
dorsal surface of the embryo. Amnion engulfs the growing embryo when it 
enlarges. 
Amnion, that contains amniotic fluid  is a avascular membrane which is a 
tough but pliable membrane at term.  For the successful pregnancy outcome, 
development of components of amniotic membrane that protect against its rupture 
is vitally important. 
 Bourne (1962) 
5
 described the layers of amnion. 
The inner surface is an uninterrupted single layer of cubical epithelium, 
which is believed to be derived from embryonic ectoderm. This inner surface is 
bathed by amniotic fluid. 
This epithelium is firmly attached to a distinct basement membrane. This 
basement membrane is connected to a acellular, compact layer. This acellular layer 
is composed of interstitial collagens. Row of  fibroblast like mesenchymal cells are 
present on the outer side of the compact layer, which are probably derived from 
embryonic disc mesoderm. Contiguous with the second fetal membrane chorionic 
leave Vs the outer most layer of amnion which is the relatively acellular Zona 
spongiosa. 
13 
The human amnion contains few fetal macrophages, but it lacks smooth 
muscle cells, nerves, lymphatics and importantly blood vessels. During early 
implantation a space develops between the embryonic cell mass and the adjacent 
trophoplasts. Inner surface of trophaplasts is lined by small cells have been called 
amniogenic cells which are precursors of ammonic epithelium. 
  
Amnion Epithelial Cells 
 The epithelial cells of the amnion are derived from fetal ectoderm of the 
embryonic disc. It is an important consideration from both functional and 
embryological perspectives. ie, HLA class I gene expression in amnion is more 
akin to that in cells of the embryo than that in trophoblasts. 
 
 Early in human embryogenesis, the amniotic measenchymal cells lie 
immediately adjacent to the basal surface of the epithelium. At this period of 
development the amnion surface is a two cell layer structure with approximately 
equal numbers of epithelial and measenchymal cells. As interstitial collagens are 
deposited between these two layers of cells, there is a formation of the compact 
layer of the amnion, which also brings about a distinct separation of the two layers 
of amnion cells. 
 
14 
 Amniotic epithelial cells have highly developed microvilli in the apical 
surface that are consistent with a major site of transfer between amniotic fluid and 
amnion. These cells syathesize tissue inhibitor or metallo proteinase – 1,  PGE 2 
and fetal fibronectin.
6
 Amniotic epithelium participates in the final common 
pathway of labour initation by prostaglandin production. 
 
 Amniotic epithelial cells may respond to variety of endocrine or paracrine 
modulators derived from fetus or the mother, oxytocin and vasopressin are the 
examples both of which increase the PGE2 production in vitro
7
 
 
 Amniotic epithelium also synthesizes vaso active peptides like endothelin 
and para thyroid hormone related protein
 8
 
 
 Brain natriuretic peptide and corticotrophin – releasing hormone are also 
produced which are the smooth muscle relaxants 
 9.
 vaso active peptides produced 
in amnion gain access to adventitial surface of chorinic vessels and may be involed 
in modulating chorionic vessel tone and blood flow. Amnion derived vasoactive 
peptides, after their secretion, enter amniotic fluid and thereby are available to the 
fetus by swallowing and inhalation.  
15 
These peptides function in other tissues in diverse physiological processes. 
Amnionic epithelial cells also produce cytokines such as IL-8 during initiation of 
labour  
10
  
 
Amnion Mesenchymal Cells 
 Measenchymal cells of the amnion are responsible for other major functions. 
Synthesis of interstitial collagens – the major source of its tensile strength takes 
place in measenchymal cells.. cytokines,  IL – 6, IL-8, and monocyte 
chemoattractant  protein – 1 (MCP – 1) are synthesized  by  mesenchymal cells. In 
response to bacterial toxins and IL– 1 cytokine synthesis will increase. 
 
 This functional capacity of mesenchymal cells of the amnion is an important 
consideration in amniotic fluid study for evidence of labour – associated 
accumulation of inflammatory mediators 
11
  
 
 Mesenchymal cells may be a greater source of prostaglandin E2 than 
amniotic epithelial cells. 
12
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Formation and sources of amniotic  fluid; 
 
The amniotic fluid  is derived  from the mother  directly  across  the  amnion  and 
the fetal surface  of the  placenta  and  fetal body surface  in  the  first trimester. 
 During embryogenesis amniotic fluid volume increases faster than 
embryonic size. There is a rapid diffusion across the embryonic skin as it is only 
four cell layers thick. 
 During the embryo-fetal development,the metanephri begin to develop by 
seven weeks menstrual age and are functional by 10-11 weeks menstrual age. 
Because glomerular filtration precedes tubular function fetal urine is initially 
relatively hypotonic.As the fetus matures,resorption of sodium,chloride and water 
occurs and the excretion of  urea and cretinine increases. 
These alterations in fetal renal  function in part explain the changes that are 
seen in the composition of amnioticfluid with advancing gestational age. 
Amnioticfluid  volume increases from 25ml at 10 weeks to about 400ml at 
20 weeks.Its  composition is similar to fetal plasma during this period. 
Not yet keratinized fetal skin allows a rapid bi directional diffusion between the 
fetus and amniotic fluid. The surfaces of the amnion, placenta and core umbilical 
cord each being freely permeable to water and solutes during this period of 
17 
pregnancy .The  amniotic fluid serves both as a physiologic buffer and an 
extension of fetal extra cellular compartment. 
 
 Even though, fetal kidneys, make urine by  8weeks of gestation, and 
swallowing begins shortly thereafter, neither fetal urination nor swallowing 
contributes significantly to the volume or content of amnioticfluid  until second 
half   of pregnancy. The fetal skin begins to keratinize at 20 weeks, process being 
completed by 25 weeks of gestation. 
 
 After the fetal skin is fully keratinized, production of AF is predominantly 
accomplished by excretion of fetal urine ( 300ml / kg fetal weight / day or 600 to 
1200ml / day near term) and the secretion of  oral nasal, tracheal and pulmonary 
fluids 60-100ml kg fetal weight / day) 
13
  
 
Near term  the  major sources   of  amniotic fluid  production are fetal urine 
and lung liquid. The major routes for resorption of fluid are fetal swallowing and 
the intra membranous pathway (from amniotic fluid to fetal circulation).The minor 
sources of amniotic fluid production and clearance include secretions from the fetal 
oral, nasal cavities and the transmembranous pathway (amniotic fluid to maternal 
circulation.)  
18 
Based on current concepts of amniotic fluid dynamics
14,
 there are six routes for 
fluid entry into and exit from the amniotic sac for the late gestation fetus; 
1. Fetal urine 
2. Fetal swallowing 
3. Oral- Nasal secretions 
4. Secretion from respiratory tract 
5. Intra membranous pathway 
6. Trans membranous pathway 
Flow in to the amniotic sac; 
Fetal urine production -800 to 1200mL/day 
Fetal lung liquid secretion -170 mL/day 
Oral-nasal secretions -25mL/day. 
Flow out of the amniotic sac; 
Fetal swallowing-500 to 1000mL/day 
Intramembranous flow -200 to 400mL/day 
Transmembranous flow -10mL/day 
 
 
19 
Fetal urine is the major contributor of the volume of amniotic fluid in the 
later half of pregnancy. The volume of urine produced by human fetus per day 
during later half of pregnancy is 35% of its body weight
15.
 
 
The fetal swallowing of amniotic fluid is evidenced by presence of 
epidermal debris including lanugo hairs in the meconium. The fetus swallows 
amniotic fluid which is equivalent to 15% of its body weight
16
. 
 
 Fetal oral and nasal secretions also enter the amniotic fluid, but less than 1% 
of the body weight per day 
17
 
 
 The pathway for exchange between amniotic fluid and the fetal blood within 
the fetal surface of placenta is referred to as intramembranous pathway. Osmotic 
flow of water and diffusion of solutes occur in this pathway, ie, water and solutes 
can move in opposite directions. 
 
 During late gestation, 400ml of water is absorbed daily intramembranously 
from amniotic fluid. 
 
20 
 Fetal lungs secrete large volumes of fluid each day and less than 1% of this 
secreted fluid is needed to expand the lungs, and the remainder flows out of the 
lungs and may either enter the amniotic fluid or be swallowed as it exits the 
trachea. The amniotic fluid from the trachea is the source of surfactants, used as an 
indicator of fetal lung maturity. Only under condition of fetal asphyxia or in severe 
distress fetal lungs absorb fluid. Although meconium staining of amniotic fluid is 
common, aspiration of meconium into the lungs of the new born is relatively 
uncommon. Lung secretions rates are approximately are 10% of fetal body weight 
daily
18
.   
 
 The passive exchange of amniotic fluid between the amniotic fluid and the 
maternal blood within the uterine wall, is known as trans membranous pathway. It 
is estimated to be as little as 10ml daily near term under normal conditions
19
. 
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CHANGES IN AMNIOTIC FLUID VOLUME ACROSS 
GESTATION 
In human pregnancy amniotic fluid volume increases dramatically during the first 
two trimesters,from 25ml at 10 weeks to 800 ml at 28 weeks.Amniotic fluid 
volume  changes in pregnancy were studied by Brace and wolf 
20
,and  observed 
that , amniotic fluid volume rises progressively during gestation until 
approximately 32 weeks.From 32 weeks to term the mean amniotic fluid volume is 
relatively constant in the range of 700-800ml.Although the average amniotic fluid 
volume in the third trimester is 700 to 800ml ,the range of normal is very wide and 
a normal fetus at 32 weeks may have more than 2000ml,or less than 500ml of 
amniotic fluid.This wide range of normal causes problem of assessing the amniotic 
fluid volume in pregnancy. 
After 40 weeks, there is a progressive decline in amniotic fluid volume at the rate 
of 8% per week, with amniotic fluid volume averaging only 400ml at 42 weeks.  
The variation in normal fluid volume below the mean value is smaller than the 
upper variation in the third trimester oligohydramnios,defined as the 5
th
 percentile  
which is approximately 300ml.Variations in the upper range is almost threefold 
greter,so that hydramnios –more than 95th percentile varies from 1700-1900ml. 
 
 
22 
 
 
 
23 
REGULATION OF AMNIOTIC FLUID VOLUME 
 
 Late in gestation when the amniotic fluid volume averages 700-800ml, 
100ml daily leaves the amniotic compartment. Only minor or moderate aberrations 
in flows readily lead to oligohydramnios or polyhydramnios. There are no known 
sensors for amniotic fluid volume, could be part of a control loop to return 
amniotic fluid volume towards normal whenever it becomes too high (or) too low.  
 
 In late gestation fetal lung and urine are the two major sources of amniotic 
fluid. Removal of fluid depends on fetal swallowing and intra membranous 
transport via skin, placental and cord surfaces.        
 
 Fetal urine flow, lung liquid secretion and swallowing are known to be 
regulated. Intra membranous absorption is controlled by factors that regulate the 
intra membranous permeability and surface area. 
 
 Recent studies
21
 suggest that even slight changes in intra membranous 
permeability can have very large effects on intra membranous fluid rates. 
 
24 
 Substances like prostaglandins excreted by fetal kidneys are released by 
amnion or chorion which enters the amniotic fluid could alter intra membranous 
permeability and thus lead to alterations in amniotic fluid volume. 
 
 Hormonal factors play a role in amniotic fluid regulation. Cortisol and 
antidiuretic hormone affect the permeability of amnion. Intra amniotic injection of 
prolactin shown to reduce  the amniotic fluid by 50% by stimulating the transport 
of water from the fetus to maternal compartment 
22 
 
OLIGOHYDRAMNIOS 
Definition: 
  Oligohydramnios is a condition in which the amount of a amniotic fluid is 
decreased less than normal  level.(normal level of AFI is 8-15cm.) 
 The definition has varied with different investigators.  
Manning et al 
23 
defined oligoamnios when the largest pocket on ultrasound in its 
largest diameter measured less than 2cm. 
  
 
Phelan 
2
 who described amniotic fluid index, defined AFI – less than 5cm as 
oligohydramnios. 
 
25 
 More recently, oligohydramnios is defined as less than 3
rd
 and 5
th
 percentile 
for the gestational age.
24
 
Definition for oligohydramnios given by various authors 
Technique    Definition   Reference 
1. Dye dilution   200ml   Horsager etal (1994) 
2. Dye dilution   500ml   Maann etal (1992) 
3. 12-studies Direct 
Measurement or dye   318ml   Brace and wolf (1989)  
Dilution 
4. Ultrasound   Single deep vertical Mercer ret al (1984) 
Pocket < 5cm 
 
5. Ultrasound   Single deep vertical Manning et al (1981) 
Pocket <1cm 
 
6. Ultrasound   Single deep vertical Manning      et al (1990) 
Pocket <2cm 
 
7. Ultrasound   Single vertical  Halpenin      et al and   
Pocket <3cm  Crawley et al (1984-85) 
26 
 
8. Ultrasound   Two diameter Pocket Magnann   et al (1992) 
(Vertical X horizontal)  
< 15cm 
 
9. Ultrasound   AFI < 5th Percentile for Moore (1990) 
gestationalage 
 
10. Ultrasound   AFI < 5cm  Phelan (1987) 
11. Ultrasound   AFI  <7cm   Dizon – Townson (1996) 
12. Ultrasound   AFI  <8cm   Jeng     et al (1992) 
 
Clinically the diagnosis of oligohydramnios is considered when the fundal 
height is small for gestational age or if the fetal parts can be easily palpated and the 
uterus feels as if it is clamped over the fetal parts,with little ballottment. 
 
Breech like malpresentations are common as there is no enough liquor  for 
the fetus to turn spontaneously. 
 
 
27 
 
Methods Of Quantification Of Amniotic Fluid 
Measurements of amniotic fluid can be made directly, indirectly (or) 
estimated sonographically. 
 
During cesarean section (or) hysterotomy 
25
 amniotic fluid volume can be 
directly measured. 
Indirect measurements are done by dye – dilution techniques via 
amniocentesis. Para – amino hippurate used dye dilution technique has been shown 
to be   representative of actual amniotic fluid volume obtained by direct 
measurement 
26
  
 
The dye injection technique is considered the gold standard for measuring 
actual amniotic fluid volume, but it is impractical to use this invasive test to 
measure amniotic fluid volume in clinical practice at risk for loss and infection. 
 
These techniques are invasive time consuming and may require laboratory 
support, hence amniotic fluid volumes are usually estimated by ultrasound. 
 
The sonographic assessment of amniotic fluid volume is semi quantitative. 
28 
Sonographic evaluation of amniotic fluid volume includes four methods: 
1. Subjective assessment 
2. Assessment of a single pocket (eg.2 x 2 measurement) 
3. Single deepest pocket or maximum vertical pocket (SDP) 
4. Amniotic fluid index(AFI) 
Amniotic fluid may be described subjectively, but accuracy is dependent on 
operator experience and gestational age. Goldstein and Filly (1988) reported good 
intraobserver and interobserver agreement between subjective assessment and 
single largest pocket determination of amniotic fluid volume. Disadvantage is an 
inability to compare results from serial examinations as the fetal or maternal 
conditions
.27 
 
In practice, the amniotic fluid volume is measured by semi quantitative 
measures like amniotic fluid index (AFI), single deepest vertical fluid pocket 
(SDP) ,or assessment of a single pocket (eg.2x2cm) 
 
Amniotic fluid index first proposed by phelan et al
2
 is the summation of the 
vertical diameter of the largest pocket in each of four quadrants. The maternal 
umbilicus is considered as a central reference point. The transducer should be 
29 
oriented in the longiudinal plane. A minimum horizontal measurement of 1cm is 
considered. Oligo hydramnios was defined as AFI <5 cm. 
Jeng and co workers 
28
 have defined oligohydramnios as an AFI <8 cm. 
They demonstrated increased incidence of meconium staining, caesarean delivery 
for fetal distress, abnormal fetal heartrate pattern and APGAR <7  at one minute 
when AFI was less than 8cm. 
 
Chamber lain 
29
 proposed the single deepest vertical pocket, and is simply 
found by identifying the largest pocket of amniotic fluid after a global assessment 
and selecting the largest vertical measurement with a minimum horizontal 
measurement of 1cm. 
 
 A two – diameter pocket (cm2) is calculated by multiplying the depth and 
width of the largest single pocket 
30
. 
 
 Magann and associates found that AFI was reasonably reliable in estimating 
normal or increased amniotic fluid but in case of oligohydramnios it was 
inaccurate. 
 
30 
 Morris and collegues (2003) 
31 
found that the AFI was superior to the single 
deepest pocket of amniotic fluid. 
 
 AFI may be modulated by several factors.  
Yancey and Richards (1994) reported that high altitude was associated with an 
increased amniotic fluid index (600 ft) 
32
.  
Maternal hydration increased the amniotic fluid index 
33 
 
 Brace and wolf 
20 
identified that from 22 through 39 weeks of gestation 
despite an increase in fetal weight from 500gm to 3500gm the average volume of 
amniotic fluid remained unchanged and this suggests that amniotic fluid volume is 
carefully regulated.  
 
Aetiology Of Oligo Hydramnios 
 A number of conditions 
34
 are associated with oligohydramnios. 
1. Fetal causes; 
- Congenital anomalies 
- Chromosomal abnormalities 
- Fetal demise 
- Growth restriction 
31 
- Post term pregnancy 
- Ruptured membranes 
 
2. Maternal causes; 
- Utero placental insufficiency 
- Hypertension 
- Pre eclampsia 
-Diabetes insipidus 
3. Drugs 
- Prostaglandin Synthesis inhibitors 
- Angiotension converting enzyme inhibitors 
4. Placental factors; 
- Abruption 
- Twin twin transfusion 
5. Idiopathic 
 
Congenital anomalies associated with Oligohydramnios
35 
I. Genito urinary: 
a) Renal agenesis, 
b) Bilateral multicystic kidneys  
32 
c) Infantile poly cystic kidney disease 
d) Renal dysplasia 
e) Urethral obstruction 
f) Bladder extrophy, 
g) Meckel – Gruber syndrome, 
h) Urethro pelvic junction obstruction  
i) Prune-belly syndrome. 
 
II. Central Nervous system: 
a) Holo prosencephaly, 
 b) meningocele, 
               c) encephalocele, 
               d) microcephaly 
 
III. Chromosomal abnormalities:       
 a) Triploidy, 
 b) trisomy 18, 
 c) Turner syndrome 
 
IV. Cardiac 
33 
a) Fallot tetralogy 
 b) septal defects 
 
V. Cloacal dysgenesis 
 
VI. Cystic hygroma 
 
VII. Diaphragmatic hernia 
 
VIII. Skeletal:  
a) Sireno melia, 
 b) sacral agenesis, 
 c) absent radius  
d) facial  clefting 
 
IX. Twin Reverse Arterial Perfusion sequence 
X. Twin –twin transfusion 
XI. VACTERL (vertebral, anal, cardiac, tracheo – esophageal, renal, limb) 
association. 
 
 The distribution of abnormalities associated with oligohydramnios in third 
trimester is different.In study by shipp et al 
36
of patients greater than 28 weeks 
34 
described a 28% rate of fetal growth restriction ,9% rate of abruption ,and a 4% 
rate of congenital anomalies.This study excluded  premature rupture of membrane 
patients ,14% of patients with oligohydramnios patients ruptured membranes after 
the diagnosis had been made. 
 
 The incidence of aneuploidy and structural malformations with 
oligohydramnios range between 4.4 – 30.7% and 7 – 37% respectively   
Oligohydramnios in the presence of IUGR, or preeclampsia has markedly worse 
perinatal outcomes .  
 
Intrauterine Growth Restriction and Oligohydramnios; 
 The association between FGR and oligohydramnios has been attributed to 
decreased fetal urine production due to decreased utero placental perfusion.  
 Fetal hypoxia causes redistribution of cardiac output to fetal brain diverting 
the blood supply away from kidney and lungs.This results in reduced fetal urinary 
production and decreased lung secretions both of which contribute to amniotic 
fluid volume. The risk of FGR progressively increases as the severity of 
oligohydramnios increases. 
 
35 
 The prevalence of IUGR is 5%,20%, and 37% respectively when a single 
pocket of amniotic fluid is >2cm,between 1&2 cm and <1 cm 
37.
 
 Besides congenital malformations and chromosomal defects the increased 
perinatal mortality can be largely explained by the conditions associated with 
oligohydramnios like   fetal growth restriction, hypertension, pre mature rupture of 
membranes and post maturity. 
 
Prolonged Pregnancies and Oligohydramnios; 
 After 38 weeks fluid volume declines by approximately 125 ml / week, to an 
average volume of 800ml at 40 weeks, and has a massive reduction by 33% per 
week after 42 weeks of gestation 
38
. The drop is attributed to reduced urine output 
by the fetus, which in turn is caused by the redistribution of fetal circulation and 
reduction in renal perfusion. The fluid becomes thick due to an increased amount 
of vernix caseosa. So, the volume is reduced and the density increased. Addition of 
meconium  in such amniotic fluid leads to respiratory complications for the new 
born baby 
. 
 
Preterm Rupture of Membranes and Oligohydramnios; 
 Spontaneous rupture of membranes between 24 and 34 weeks gestation 
occurs in 1.7% pregnancies.
36
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Maternal Hypovolemia and Oligohydramnios; 
 The other factors that affect amniotic fluid are maternal hydration and fetal 
presentation. Oligohydramnios in association with acute maternal hypovolaemia 
improved with intravenous hydration.
39
The changes in amniotic fluid volume is 
mediated by changes in intra membranous flow. A significant increase in amniotic 
fluid volume in women with oligohydramnios have confirmed after oral or 
intravenous hydration. 
40
 
 
Iatrogenic Oligohydramnios; 
 First trimester chorionic villus sampling and second trimester amniocentesis  
are associated with oligohydramnios. The  neonatal outcome is good if 
amnioticfluid volume returns to normal subsequently.
41
 
 Drugs like prostaglandin synthetase inhibitors inhibit renal vascular flow & 
thereby reduce amniotic fluid volume. They also cause closure of ducts arteriosus
42 
.Amniotic fluid reaccumulates when these drugs are discontinued. When late 
second or third trimester women are given prostaglandin synthetase inhibitors, 
serial ultrasound examinations are warranted.   
37 
 Angiotensin converting enzyme inhibitors are associated with 
oligohydramnios and growth restriction and anuria.
43
 
 These drugs cause fetal renal damage, including renal tubular dysgenesis and 
renal failure. 
 
Isolated Oligohydramnios;  
 Isolated oligohydramnios may occur in late pregnancy may be incidentally 
diagnosed on a routine ultrasound in patients with no other high risk factors 
associated with oligohydramnios. RADIUS trial in which low risk women had a 
routine ultrasound at 15-22 and at 31-35 weeks, 0.8% had oligohydramnios, of 
which about 50% had isolated oligohydramnios. The perinatal outcomes were 
similar to those with normal amniotic fluid volume 
44
  
 
 Labour induction is attempted in these cases in spite of their cervix is 
unfavourable  for induction .This can often result in caesarean section delivery for 
failed induction.  
 
Maternal effects of oligohydramnios 
 Oligohydramnios may be associated with an increase in maternal 
complications.Premature rupture of membranes is associated with increased risk of 
38 
chorioamnionitis and maternal morbidity.Obstetric  risks observed  are  an 
increased risk for caesarean delivery  and  increased risk for labour induction.  
Fetal effects of oligohydramnios 
 
Reduced amniotic fluid in the first trimester is an ominous finding, the 
pregnancy often aborts. In one study 94% with smallsac and a normal heart rate 
spontaneously abort compared with only 8% with normal sac size
. 45 
 
In  the second trimester the prognosis depends on the  underlying etiology 
and severity of  the oligohydramnios. Pregnancies with isolated  mild or moderate 
idiopathic oligohydramnios  have a good prognosis, but in contrast  severe second 
trimester oligohydramnios  results in fetal or neonatal death. 
 
Early onset oligohydramnios has significant perinatal morbidity and 
mortality due to associated congenital anomalies, pulmonary hypoplasia. 
 
Oligohydramnios concurrent with early onset fetal growth restriction and 
hypertension, and PPROM contributed to perinatal morbidity and mortality. 
 
In particular, severe oligohydramnios due to PPROM in the second trimester 
is associated with increased perinatal mortality when the duration of the latency 
39 
period is more than 14 days.
45
 The key element for survival is the presence of 
atleast some amniotic fluid between 18 and 23 weeks gestation. Absence of 
amniotic fluid during this interval regardless of the mechanism is highly associated 
with increased perinatal mortality. 
 
Preterm delivary occurs in >50% of pregnancies with severe second 
trimester oligohydramnios either spontaneously or indicated by maternal or fetal 
complications. 
 
Surviving infants of second trimester severe oligohydramnios cases may 
have significant morbidities. Infants may have anatomic and functional 
abnormalities. 
 
  Fetal deformities with oligohydramnios include potter facies (low set 
ears,epicanthic folds, receding mandible and flattened nose) and abnormal position 
of feet and hands 
45 
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The presence of oligohydramnios in second trimester markedly increases the 
fetal risk for pulmonary hypoplasia. There are 3 possibilities that account for 
pulmonary hypoplasia. First one thoracic compression may prevent chest wall 
excursion and lung expansion. Second, lack of breathing movements decreases 
41 
lung inflow. The third and the most widely accepted model involves a failure to 
retain amniotic fluid or increased outflow with impaired lung growth and 
development 
46 
 
Although newer interventions such as inhaled nitric oxide and high 
frequency ventilation have improved survival in this condition, pulmonary 
hypoplasia presents a threat to the survival of the fetus
.45
   
 
The prognosis of third trimester oligohydramnios is not fearful as second 
trimester oligohydramnios. Most cases of severe oligohydramnios in the third 
trimester occurred at or near term, and they are not associated with Potter-like 
effects ,but they are often associated with fetal growth restriction. It was shown 
that an inverse relationship between amniotic volume in the third trimester and the 
incidence of adverse pregnancy outcome. Adverse outcomes are related to 
umblicalcord compression , utero placental dysfunction ,and meconium aspiration. 
Women with oligohydramnios have a significantly increased risk for caesarian 
delivery for fetal distress and for a 5 minute APGAR score of less than 7 due to 
associated cord compression and uteroplacental dysfunction 
47 
 
42 
 
There is a 50% increase variable decelarations during labour and a 
severalfold increase in caserean delivery rate in woman with oligohydramnios
48
  
 
Variable  Deceleration  
 They are decelerations which are variable in their relation to uterine 
contraction; they may (or) may not come with every contraction. They may come 
variably during any phase of contraction – ‘M’ shape of trace    is usually found in 
CTG, in variable deceleration 
49 
 
 
Intensity of uterine contraction is unrelated to the decelerations. 
Decelerations usually vary in degree of fall of FHR and also in their duration. 
 
 Variable decelerations arising from a disturbance in blood flow through the 
umbilical cord are due to its varying degrees of cord compression. 
 
 Events in the earlier or milder stages of cord compression are due to 
obstruction in venous blood flow, which leads to decreased venous return to fetal 
heart. There will be a compensatory tachycardia in order to maintain the blood 
pressure. The first peak of the ‘M’ shape tracing co-insides with this spurt of 
tachycardia. 
43 
 
 Events in more severe or late stage of cord compressions are due to arterial 
blood flow obstruction which leads to increased peripheral resistance and rise of 
blood pressure. Activation of vagal centre in the brain by activation of aortic 
stretch receptors causes tachycardia. The middle dipped portion of ‘M’ is due to 
this crust. It is how the fetus attempts to restore its blood pressure to normal level. 
 
2
nd
 peak of ‘M’ is caused by reactive tachycardia once the occlusion of cord 
was over. Oligo hydramnios causes higher chances of cord compression and it is 
the basis of giving amino infusion in these cases.  
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Doppler examination, cord – compression is found to cause the end diastolic blood 
flow through the umbilical artery to be absent or even reversed. 
 
 Absent (or) reversed end diastolic flow develops when  60-70% of placental 
villous vasculature  is abnormal. 
 
 Fetuses with absent end – diastolic flow should be delivered as a general 
guide like, if at or near should be intensively monitored by daily CTG and 
biophysical profiles.  
 
46 
Oligohydramnios was associated with increased risk of meconium aspiration 
syndrome, stillbirth and neonatal death.
3 
 
It is widely believed that any insult causing hypoxia in fetus will cause fetal 
hyperperistalsis and relaxation of the fetal anal spincter 
50 
 
Hon suggested parasympathetic stimulation from cord compression may 
stimulate meconium passage without concomitant hypoxia. Whatever be the 
stimulus ,once meconium has been passed , either fetal gasping or respiratory 
attempts by the fetus can cause aspiration of amnioticfluid containing meconium 
into the fetal tracheo bronchial tree.Meconium aspiration thus occurring can 
obstruct the airway;interfere with gas exchange and cause severe respiratory 
distress. 
 
The incidence of small for gestational age babies is significantly higher in 
the oligohydramnios group.  
 
Management of oligohydramnios 
The management of oligohydramnios depends on the gestational age and on 
the associated pregnancy complication.  
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Maternal hydration oral (or) intravenous has been shown to increase 
amniotic fluid Volume. Maternal hydration is commonly used, in an attempt to 
increase amniotic fluid volume in patients without fetal urinary tract abnormalities. 
Intravenous hydration with two liters of isotonic ringer lactate was effective in 
increasing aminotic fluid volume 
51
Amnio infusion a technique by which normal 
saline is instilled into the amniotic cavity by the trans abdominal or trans cervical 
route. 
 
Ante partum amino infusion   showed a benefit in cases a preterm premature 
rupture of membranes. The neonatal survival, pulmonary hypoplasia and PPROM 
delivery interval were significantly better with serial amino infusion. Risk of 
abnormal neurological outcome in survivors was significantly less in pregnancies 
where amino infusion was successful 
52
 
 
Intrapartum amnio infusion for meconium stained liquor showed that amino 
infusion was associated with a significant reduction in heavy meconium staining of 
liquor, variable fetal heart decelarations and reduced caesarean section rate 
53 
 
Fetal surgical approaches to the management of oligohydramnios are for 
bladderdrainage and tracheal occlusion.In cases of fetal urinary outflow 
48 
obstruction and associated oligohydramnios, a vesico amniotic shunt may be 
inserted although there is significant risk of PPROM. There is no confirmed value 
in preserving renal function despite the use of fetal urinary electrolytes to select 
patients with functioning kidneys for treatment. 
 
Fetoscopic tracheal occlusion has been employed to alleviate or prevent 
pulmonary hypoplasia associated second trimester oligohydramnios. 
 
Ross and colleagues 
54
1996 found that DDAVP –l-deamino-8-D arginine 
vasopressin increases the amniotic fluid index in cases of oligohydramnios.The 
increase in AFI is attributed to the maternal serum hypo osmolality caused by 
DDAVP. 
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HYDRATION THERAPY GENERAL CONSIDERATIONS 
 
 Intravenous hydration (or) oral hydration significantly increases the  
amniotic fluid volume 
40 
in women with oligohydramnios. This increase in 
amniotic fluid volume whether results from an improved utero placental circulation 
and increased fetal urination or as a direct effect of decreased oncotic pressure in 
the maternal circulation is uncertain.  
 
Changes in maternal intravascular volume alter the fetal urine output, 
amniotic fluid volume and intra vascular volume to some extent.
55
 
Maternal hydration acts by 2 mechanisms, 
 
Decrease in maternal plasma osmolality results in fetal hypoosmolality and 
increased fetal urine output. 
 
Intra membranous amniotic fluid resorption is reduced in response to fetal 
plasma hypoosmolality. 
 
Magann et al reported that intravenous hydration therpy with isotonic 
solution causes elevated levels of amniotic fluid index.
56
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Hydration of mothers in term pregnancy and oligohydramnios caused the 
amniotic fluidvolume to increase with mean change of AFI 4.5cm.
57 
 
Improvements of utero placental perfusion due to plasma volume increase in 
mothers would increase renal blood flow and fetal oxygenation is improved. The 
decrease in vasopressin and increase in urinary output would be observed.
58
. Fetus 
is compensating by reducing plasma osmolality and increasing urinary output 
which inturn increases the amniotic fluid volume for the acute changes in maternal 
plasma osmolality.
  
 
Doi et al showed maternal hydration modified their osmolality and thus 
increased amniotic fluid volume.
59
   
 
Kilpatrick and saford 
33
 showed after maternal hydration there is a 
significant increase in the mean arterial flow velocity. Hydration may increase 
amniotic fluid index by improving blood flow of the placenta. 
  
Intravenous hydration therapy with 6500ml of an isotonic solution increased 
amnioticfluid volume in dehydrated women. (sherer 1990).
45 
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MATERIALS AND METHODS 
 A prospective study on the effect of intravenous hydration therapy in cases 
of third trimester oligohydramnios and its effects on perinatal outcome was carried 
out in, 
 
 Government Stanley Medical college, Chennai – 1, during the period of 
January 2015 to August 2015. 
 
Inclusion Criteria: 
1. The pregnant women Whose amniotic fluid index <5cm 
2. Third trimester 
3. Singleton pregnancy 
4. Intact membranes 
 
Exclusion Criteria;   
1. Multiple gestations 
2. Rupture of membranes 
3. Any evidence of fetal structural abnormalities in       
ultrasound studies 
4. Multiple gestations 
53 
 Maternal complications like, 
a) Diabetes mellitus 
b) Cardiovascular disease 
c) Hyper thyroidism  
d) Chronic obstructive pulmonary disease 
e) Renal disease 
f) First & Second trimester oligohydramnios 
g) IUD 
 
Sample Size 
 About 150 cases in third trimester with amniotic fluid index- AFI <5cm 
(Study group) 
 And 150 cases in Control Group (AFI >5cm) 
Period of study: 1year  
Design of syudy: Case-control study 
History regarding age, parity, gestational age, menstrual history, obstetric 
history and co-morbidities in present pregnancy, H/o premature rupture of 
membranes was taken.  
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The patient was informed about my study and consent was taken. 
150 patients in third trimester pregnancy with oligohydramnios in one group 
and 150 normal pregnancy patients in third trimester were taken as control group. 
 
General clinical examination was done. Pulse rate, Blood pressure, 
temperature, Height of patient, Weight of the patient were noted. Symphysio 
fundal height and adequacy of amniotic fluid were clinically noted. Fetal heart rate 
was counted. Speculum, examination was done to rule out draining plv and 
confirmed the presence of membranes.  
 All routine investigations done 
 A non-stress test was done. 
 Amniotic fluid index was measured by the technique described by phelan  et 
al
2
. 
 Ultrasound examination was carried out after instructing the patient to empty 
her bladder. Patient was asked to lie down in supine position. 
 A curvilinear transducer is used 
55 
 By marking the uterus is divided into four quadrants using the maternal 
sagital midline vertically and an arbitrary transverse line approximately half way 
between the symphysis pubis and upper edge of uterine fundus. 
 
 The transducer was kept parallel to the maternal sagittal plane and 
perpendicular to the maternal coronal plane throughout. 
 
 The deepest, clear pocket of amniotic fluid excluding the cord loops and 
small fetal parts visualized and image was frozen. The ultrasound calipers are 
manipulated in such a way to measure the pocket in a strictly vertical direction. 
The process is repeated on each of four quadrants and measurements are summed 
up to calculate the AFI. Caution was exercised to avoid excessive pressure on the 
transducer as if can alter AFI measurements. 
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Patients are grouped according to their AFI 5cm  or less as cases  and control 
group as their AFI  > 5cm.  
  Starting from 34 weeks till 40 weeks the mean (standard deviation) of AFI 
values (in cms) were, 
 34 weeks : 14.59 (1.79) 
 35 weeks : 14.25 (1.57) 
 36 weeks : 13.17 (1.56) 
 37 weeks : 12.48 (1.52) 
 38 weeks : 12.2    (1.7 ) 
 39 weeks : 11.37 (1.71) 
The 5th percentile cut off was 8.7CM AT 40 weeks. 
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Oligo hydramnios group of patients are admitted. Admission test (CTG) was 
done. On admission USG done to rule out renal tract and other abnormalities. 
Doppler study of umbilical artery performed and the S/D ratio recorded. An 
increased S/D ratio in oligohydramnios cases identified the fetuses at risk of 
perinatal outcome. Continous intra partum monitoring was offered  to these cases 
to detect early signs of hypoxia and performed  timely intervention. 
57 
Maternal hydration in the form of isotonic Ringer lactate solution 1000 
ml/day was given intravenously every day to the oligo hydramnios group of 
patients.  
 
The mothers vital parameters were monitored to identify early signs and 
symptoms of over load. Non – stress test was performed everyday for fetal well 
being. AFI was repeated on every 3
rd
  day. Doppler study of umbilical artery and 
middle cerebral artery done every week. If any abnormality in Doppler study was 
diagnosed, pregnancy is terminated.  
 
 Maternal hydration is continued till 37 completed weeks or tests indicate 
serious fetal compromise or the Fetus has reasonable chances of survival. 
 
 Labour induction is done according to the Bishop score of individual 
patients. Cases are followed up with observing mode of delivery, indication for 
LSCS, colour of the liquor, APGAR, reason for NICU admission, Birth weight, 
and condition of the baby on discharge.  
 
The following study outcomes are noted: Effect of intravenous hydration by 
means of increase in amniotic fluid index(AFI) ,and the perinatal outcome between 
58 
intravenously hydrated oligohydramnios cases, and normal pregnant cases are 
noted. 
Data analysis was done with use of SPSS, version 18. 
The results were expressed in terms mean ± Standard deviation; analysis of 
the result was done using paired t test, chi-square test. 
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ANALYSIS OF STUDY OBSERVATIONS 
TABLE – 1 
AFI after Hydration Therapy 
 Mean N Std 
Deviation 
P-Value 
Pre Treatment 
AFI 
4.965 150 2326  
< 0.001 
Post Treatment 
AFI 
6.844 150 3500 
 
 In this study there is a significant increase in AFI after intravenous hydration  
therapy in third trimester oligohydramnios cases. 
In our study the mean duration of hydration therapy is 1.2 weeks. 
Mean increase in amniotic fluid index in hydrated group is from 
4.965 to 6.844. Mean difference is 3.0cm 95% CI (P=<0.001) 
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Age in Years  
Table – 2 
 Age 
Group in 
years 
  Group 
Total 
  
P 
value 
  Control Cases 
<= 20 
  
  
Count 22 12 34  
 
 
 
 
 
 
 
 
 
 
 
 
0.096 
% within 
Age Group 
in years 
64.7% 35.3% 100.0% 
% within 
Group 
14.7% 8.0% 11.3% 
21-30 
  
  
Count 125 131 256 
% within 
Age Group 
in years 
48.8% 51.2% 100.0% 
% within 
Group 
83.3% 87.3% 85.3% 
> 30 
  
Count 3 7 10 
% within 30.0% 70.0% 100.0% 
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  Age Group 
in years 
% within 
Group 
2.0% 4.7% 3.3% 
 Total Count 150 150 300 
% within 
Age Group 
in years 
50.0% 50.0% 100.0% 
% within 
Group 
100.0% 
100.0
% 
100.0% 
                                                                               P=0.96 
In this study majority of cases are in the age group of 21 – 30 yrs. 
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Age in Years 
Table – 2 
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Distribution of Cases with Parity 
Table - 3 
    Group Total 
    Control Cases   
Parity Primi Count 84 81 165 
    % within 
Parity 
50.9% 49.1% 100.0% 
    % within 
Group 
56.0% 54.0% 55.0% 
  Multi Count 66 69 135 
    % within 
Parity 
48.9% 51.1% 100.0% 
    % within 
Group 
44.0% 46.0% 45.0% 
Total Count 150 150 300 
  % within 
Parity 
50.0% 50.0% 100.0% 
  % within 
Group 
100.0% 100.0% 100.0% 
                                                                                             P=0.184 
In hydration therapy received group 81Cases were primi gravida, 69 Cases 
were multi gravida. 
In Control Group 84 Cases were primi gravida and 66 cases were multi 
64 
Distribution of Cases with Parity 
Table - 3 
 
 
 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Primi Multi 
84 
66 
81 
69 
Cases 
Control 
65 
Non – Stress  test 
Table - 4 
NST 
  
Group Total 
  
  Control Cases   
 Count 142 136 278 
  
 Reactive 
% within 
NST 
51.1% 48.9% 100.0% 
% within 
Group 
94.7% 90.7% 92.7% 
    Count 8 14 22 
  
Non 
Reactive 
% within 
NST 36.4% 63.6% 100.0% 
  % within 
Group 
5.3% 9.3% 7.3% 
 
 
    Total 
Count 150 150 300 
% within 
NST 
50.0% 50.0% 100.0% 
% within 
Group 
100.0% 100.0% 100.0% 
 
                                                                P=0.163 
In this hydration therapsy received group had 9.3% non –Reactive 
CTG.. 
  In Control Group 5.3% had Non – reactive CTG 
  The difference is non – significant.  
66 
Non – Stress  test 
Table - 4 
 
 
 
 
 
 
0 
20 
40 
60 
80 
100 
120 
140 
160 
Reactive Non Reactive 
142 
8 
136 
14 
Cases 
Control 
67 
Mode of Delivery 
Table – 5 
  Group Total 
Mode of Delivery Control Cases   
 
 
Normal 
Count 73 62 135 
% within Mode 
of Delivery 
54.1% 45.9% 100.0% 
 % within Group 48.7% 41.3% 45.0% 
 Count 25 22 47 
Outlet % within Mode 
of Delivery 
53.2% 46.8% 100.0% 
 % within Group 16.7% 14.7% 15.7% 
 
 
LSCS 
Count 52 66 118 
% within Mode 
of Delivery 
44.1% 55.9% 100.0% 
 % within Group 34.7% 44.0% 39.3% 
 Count 150 150 300 
Total % within Mode 
of Delivery 
50.0% 50.0% 100.0% 
 % within Group 100.0% 100.0% 100.0% 
                                                                                                     P=0.489 
In Hydration therapy group 62 cases had normal delivery, 22 cases had 
outlet forceps delivery 66 cases had Caesarean Section. 
 
In control group, 73 cases had normal delivery, 25 cases had outlet forceps, 
delivery, 52 cases had Caesarean Section delivery. 
 
The difference was found to be non – significant.  
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Mode of Delivery 
Table – 5 
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LSCS Indication 
Table – 6 
  
 
LSCS 
Indication 
  
  
Group Total 
Control Cases   
 
 
FD Count 13 23 36 
  % within LSCS 
Indication 
36.1% 63.9% 100.0% 
  % within Group 25.0% 34.8% 30.5% 
 
 
      FI 
Count 15 18 33 
% within LSCS 
Indication 
45.5% 54.5% 100.0% 
% within Group 28.8% 27.3% 28.0% 
  
  
   Others 
  
Count 24 25 49 
% within LSCS 
Indication 
49.0% 51.0% 100.0% 
% within Group 46.2% 37.9% 41.5% 
 
Total 
Count 52 66 118 
% within LSCS 
Indication 
44.1% 55.9% 100.0% 
% within Group 100.0% 100.0% 100.0% 
                                                                                                      P=0.489 
 
In  hydration therapy received group, 23 cases underwent Cesarean Section 
for fetal distress, 
In control group 13 cases underwent Caesarean Section for fetal distress. 
The difference was in significant.  
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LSCS Indication 
Table – 6 
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Liquor 
Table – 7 
  Group Total 
  Control Cases   
 Count 134 127 261 
Clear % within Liquor 51.3% 48.7% 100.0% 
 % within Group 89.3% 84.7% 87.0% 
 
Moderate       
MSAF 
 
 
Count 0 3 3 
% within Liquor .0% 100.0% 100.0% 
% within Group 
.0% 2.0% 1.0% 
 
 
Thin 
MSAF 
 
Count 16 20 36 
% within Liquor 44.4% 55.6% 100.0% 
% within Group 
10.7% 13.3% 12.0% 
 
 
Total 
Count 150 150 300 
% within Liquor 50.0% 50.0% 100.0% 
% within  
Group 
100.0% 100.0% 100.0% 
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In Hydration therapy received group 127 cases had clear liquor ,20 cases had 
thin Meconium Stained amniotic Fluid,3 cases had Moderate Meconium Stained 
amniotic Fluid. 
In control group 134 cases had clear liquor, 16 cases had thin Meconium 
Stained amniotic Fluid and No cases had Moderate Meconium Stained amniotic 
Fluid. 
The difference was found to be non – significance. (P=0.163) 
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Liquor 
Table – 7 
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1 min APGAR 
Table – 8 
 
1 min 
APGAR  
  
Group Total 
Control Cases   
 
 
 
<= 6 
Count 35 61 96 
% within 1 
min APGAR 
36.5
% 
63.5% 100.0% 
 % within 
Group 
23.3
% 
40.7% 32.0% 
 
 
 
> 6 
 
Count 115 89 204 
% within 1 
min APGAR 
56.4
% 
43.6% 100.0% 
% within 
Group 
76.7
% 
59.3% 68.0% 
 
 
Total 
Count 150 150 300 
% within 1 
min APGAR 
50.0
% 
50.0% 100.0% 
% within 
Group 
100.0
% 
100.0% 100.0% 
 
In hydration therapy received group 48 cases had 5min APGAR < 7 
In Control group 26 cases had 5min APGAR > 7  
 
75 
1 min APGAR 
Table – 8 
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5 min APGAR 
Table – 9 
 5min 
APGAR 
Group Total 
Control Cases   
<= 7 
  
Count 26 48 74 
% within 5 
min APGAR 
35.1% 64.9% 100.0% 
  % within 
Group 
17.3% 32.0% 24.7% 
     > 7 Count 124 102 226 
 % within 5 
min APGAR 
54.9% 45.1% 100.0% 
 % within 
Group 
82.7% 68.0% 75.3% 
Total Count 150 150 300 
% within 5 
min APGAR 
50.0% 50.0% 100.0% 
% within 
Group 
100.0% 100.0% 100.0% 
 
In a hydration therapy received group 48 cases had 5 minutes APGAR 
< 7  
In control group 26 cases had 5 minutes APGAR < 7 
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5 min APGAR 
Table – 9 
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Birth Weight in kg 
Table – 10 
Birth 
Weight 
in kg 
  
  
Group Total 
Control Cases   
 
 
< 2 
Count 7 7 14 
% within Birth 
Weight in kg 
50.0% 50.0% 100.0% 
 % within Group 4.7% 4.7% 4.7% 
 
 
2.0-2.5 
Count 31 66 97 
% within Birth 
Weight in kg 32.0% 68.0% 100.0% 
 % within Group 20.7% 44.0% 32.3% 
 
 
2.5-3.0 
Count 80 58 138 
% within Birth 
Weight in kg 58.0% 42.0% 100.0% 
 % within Group 53.3% 38.7% 46.0% 
 
 
> 3.0 
Count 32 19 51 
% within Birth 
Weight in kg 62.7% 37.3% 100.0% 
 % within Group 21.3% 12.7% 17.0% 
 
Total 
Count 150 150 300 
% within Birth 
Weight  
50.0% 50.0% 100.0% 
in kg 
% within Group 100.0% 100.0% 100.0% 
In maternal hydration received group 66 babies were birthweight 
between 2.0 to 2.5 kg,but in control group 31 babies were birth 
weight between 2.0 to 2.5 kg.But the difference is insignificant.  
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Birth Weight in kg 
Table – 10 
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Admission in NICU 
Table – 11 
Admissiomn in NICU 
  
Group Total 
Control Cases   
Yes Count 19 29 48 
% within 
Admissiom
n in NICU 
39.6% 60.4% 100.0% 
  % within 
Group 
12.7% 19.3% 16.0% 
  Count 131 121 252 
No % within 
Admissiom
n in NICU 
52.0% 48.0% 100.0% 
  % within 
Group 
87.3% 80.7% 84.0% 
  Count 150 150 300 
Total % within 
Admissiom
n in NICU 
50.0% 50.0% 100.0% 
% within 
Group 
100.0% 100.0% 100.0% 
                                                                                                P=0.656 
Admission in NICU in Hydration therapy received cases were – 29 – ie 
19.3% 
In control group only 19 cased ie 12.7% were admitted in NICU but the 
difference was non –significant.  
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Admission in NICU 
Table – 11 
 
 
 
 
0 
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40 
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80 
100 
120 
140 
Yes No 
19 
131 
29 
121 
Control 
Cases 
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Condition at Discharge 
Table – 12 
 
Condition at Discharge 
   
Group Total 
Control Cases   
 
 
 
Good 
Count 17 27 44 
% within 
Condition at 
Discharge 
38.6% 61.4% 100.0% 
 % within 
Group 
89.5% 93.1% 91.7% 
 
 
 
Died 
Count 2 2 4 
% within 
Condition at 
Discharge 
50.0% 50.0% 100.0% 
 % within 
Group 
10.5% 6.9% 8.3% 
 Count 19 29 48 
 
Total 
% within 
Condition at 
Discharge 
39.6% 60.4% 100.0% 
% within 
Group 
100.0% 100.0% 100.0% 
 
In this study, 2 Neonatal deaths observed in both study group and the control 
group 
The difference is non – significant. (P=0.656) 
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Condition at Discharge 
Table – 12 
 
 
 
 
 
0 
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10 
15 
20 
25 
30 
Good Died 
17 
2 
27 
2 
Control 
Cases 
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Maternal Morbidity 
Table – 13 
 
Maternal Morbidity 
  
  
Group Total 
Control Cases   
 
 
 
Maternal 
Count 150 150 300 
% within 
Maternal 
Morbidity 
50.0% 50.0% 100.0% 
 % within 
Group 
100.0% 100.0% 100.0% 
 
 
 
Morbidity 
Count 150 150 300 
% within 
Maternal 
Morbidity 
50.0% 50.0% 100.0% 
 % within 
Group 
100.0% 100.0% 100.0% 
 
There was no Maternal Morbidity in both the groups observed. 
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Maternal Morbidity 
Table – 13 
 
 
 
 
0 
20 
40 
60 
80 
100 
120 
140 
160 
Materanal Morbidity 
150 150 150 150 
Control 
Cases 
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Perinatal Out Come 
Table  14 
Hydration Therapy Group Control 
             
No                       % 
           
         No                        % 
Mode of Delivery 
Vaginal 
Outlet 
LSCS 
 
62 
22 
66 
 
41.3% 
14.7% 
44.0% 
 
73 
25 
52 
 
48.7% 
16.7% 
34.7% 
APGAR at 5 min 
< 7 
         < 7 
 
48 
102 
 
32.0% 
68% 
 
26 
124 
 
17.3% 
82.7% 
NICU Admission 29 19.3% 17 12.7% 
Neonatal death 2 6.9% 2 10.5% 
 
 In this study there is no statistical difference between mode of 
delivery, APGAR at 5 minutes, number of NICU admission and number of 
neonatal deaths in between the groups. 
In this present study there is no statistical difference in perinatal outcome 
between the hydration therapy received study group with AFI <5cm and  the   
control group who’s AFI were within normal limits.  
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Perinatal Out Come 
Table  14  
 
 
 
 
 
 
62 
102 
29 
2 
73 
124 
19 
2 
0 
20 
40 
60 
80 
100 
120 
140 
Mode of 
Delivery 
APGAR at 5 
min 
NICU 
Admission 
Neonatal 
death 
Hyd.Therapy Group 
Control 
88 
DISCUSSION 
Third trimester oligohydramnios with AFI less than or equal to 5cm is 
associated with increased perinatal morbidity and mortality. 
 
Hydration status and maternal plasma osmolality can alter amniotic fluid volume
61
.  
 
Megann et al reported elevated levels of amniotic fluid index after  
intravenous hydration using isotonic solution. 
 
In this study 150 patients with oligohydramnios in third trimester with  
AFI – 5 cm received intravenous hydration with 1000ml of isotonic solution 
per day with mean duration of hydration therapy 1.2 weeks and were compared 
with 150patients with normal AFI. 
 
Both the group were matched with respect of age, parity and gestational age. 
In a study by patreli T. S et al. AFI <5cm isolated oligohydramnios group in 
third trimester received 6 days of intravenous hydration therapy and AFI measured. 
At recruitment it was 39.68 ± 11.11mm. 
89 
In a hydrated group AFI was ± 112.45 (P < 0.001). 
There was no statistical difference in the caesarean delivery rates between 
groups. 
 
From the analysis of indication for Caesearean Section, in study group 25% 
of them were performed due to non-reactive NST. 
 
There is significant increase in AFI in study group in this study. 
 
 In our present study also there is no statistically significant difference 
in the caesarean delivery rates between groups. This is correlating with the study 
by patrili et el 
62 
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Effect of Maternal Hydration 
 Pre treatment AFI – 
(cm) 
Post treatment AFI 
(cm) 
P – Value 
Present study 4.965 ± 2.32         6.844 ± 3.35 < 0.001 
Tito silvio patreli and 
co workers (2012) 
           
           3.968 ± 1.11 
       
         7.77 ± 1.503 
 
< 0.001 
 
In present study there is significant increase in AFI, after maternal hydration 
(P - < 0.001)  
Effect of maternal Hydration 
20-30% improvement in AFI and a reduction in cesarean delivery is 
evidenced after either oral or intravenous maternal hydration in singleton 
pregnancies with isolated oligohydramnios
63
. 
 
This study by Brain S carter et al correlates with our present study. 
 
66 cases had caesarean delivery in study group and 52 cases had caesarean 
delivery in control group. 
91 
There is no statistical difference in rate of caesarean delivery in maternal 
intravenous hydration received study group and the control group.  
 
In a study conducted by Mahnaz shahnazi et al 
64
 found significant increase 
in mean amniotic fluid index in a hydrated group from 4.7 to 6.25cm.mean 
difference 1.5cm 95%CI (P=<0.001).meconium staining liquor was observed  in 
20% of cases and 36.4% of the controls which showed no significant difference. 
 
Caesarean section was performed in 30% of the hydrated group and 45.5% 
of the control group. The difference between the two groups was not statistically 
significant. 
 
In our present study there is significant increase in post treatment AFI in a 
hydrated group.(P=<0.001).  
Mean increase in amniotic fluid index in hydrated group is from 4.965 to 
6.844. Mean difference is 3.0cm 95% CI (P=<0.001) 
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In this present study meconium staining liquor was observed in 15.3% of 
cases and 10.7% of the controls. there is no significant difference. 
Caesarean section was performed in 34.7% of the hydrated group and 25% 
of the control group. The difference between the groups was statistically non 
significant.(P=0.489). 
 
This is correlating with the study by Mahnaz shahnazi et al. 
Fait et al (2003) studied effect of one week of maternal hydration.There was 
increase in AFI .They conclude that maternal intravenous hydration appers to 
increase both the actual and ultrasound estimated amniotic fluid volume
.65 
 
In our present study also after a mean duration of 1.2 weeks of intra venous 
hydration therapy there is a significant increase in AFI. 
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SUMMARY 
In this study effect of intravenous maternal hydration therapy in patients in 
third trimester with oligohydramnios AFI <5 cm was studied and perinatal out 
come in this study group is compared with the control group who were  patients in 
third trimester of pregnancy with normal AFI. 
 
About 150 cases were studied in each group. 
The following points were summed up after analyzing the antepartum period  
during which hydration therapy was given to the  oligohydramnios group  ,the intra 
partum course and the perinatal outcome. 
 
1.87.3%in study group and 83.3% in control group were in the age group 
between 21-30 yrs. 
 
In study group 54% were primi gravida and 46 % were multi gravida. 
In control group 56% were primi gravidaand 44% were multi. 
2. In a study group post treatment  AFI was found to be significantly 
increased (  P =<0.001) 
94 
3.   In a study group 9.3% had non- reactive CTG during treatment and 5.3%  
in control group patients with normal AFI  had non Reactive CTG on admission. 
The difference was not significant (P=0.18) 
 
4. In a study group 15.3% had meconium stained liquor and 10.7% in 
control group had meconium stained liquor and the difference was found to be non 
– significant (p=0.163) 
 
5. In a study group41.3% had normal delivery 14.7 had forceps, and 
44% had normal delivery, 16.7% had out let forceps delivery and 34.7% had 
LSCS. The difference was found to be non significant. (p = 0.255). 
 
 
6. In study group 34.8% were taken up for LSCS  for fetal distress and 
25% of control group were taken up for LSCS for fetal distress and the difference 
was non- significant ( P =0.489 ) 
 
7. In a study group32.0% had APGAR score <7 @ 5 min VS 17.3%  in 
control group the difference was found to be non- significant( P =003) 
95 
8. The NICU admission in study group was 19.3% vs 12.7% in control 
group. The difference was found to be not significant (P = 0.115) 
9. IN NICU admissions In study group 93.1% were in good condition at 
discharge and 2 cases died. 
In control group 89.5% were in good condition at discharge and 2cases died 
and the difference was non significant. 
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CONCLUSION 
Intravenous maternal hydration therapy with isotonic solution significantly 
increases AFI in third trimester oligohydramnios. 
 
Intravenous maternal hydration therapy is not associated with any adverse 
maternal outcomes in third trimester oligohydraminos  patients. 
 
Intravenous maternal hydration therapy in third trimester oligohydramnios is 
associated with as similar perinatal out come as in patients with normal AFI in 
third trimester. 
 
Intravenous maternal hydration therapy needs further studies, with large 
sample size, regarding materials and perinatal outcome. 
 
This study was not designed for the mechanism of increase in AFI. 
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SUGGESTION 
Oligohydramnios  and  its  complications  cause  the  mother  and  the  fetus  
to suffer. Intra venous hydration therapy   to   the mother   is a low cost method 
with   no    complications to the mother. More research   with higher number   of   
cases   is necessary to confirm the benefits. If confirmed the need for preterm 
termination of the pregnancy due to isolated oligohydramnios will be eliminated. 
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PROFORMA 
Serial Number                                                                                                                     DATE: 
NAME:                                                                              AGE:                        
 IP NO:                                                                                                               
D.O.A:                                                     D.O.D                                                
ADDRESS & CONTACT NO: 
OBSTETRIC CODE: 
LMP:                                                        EDD:                                               GA Weeks: 
PRESENTING  COMPLAINTS: 
 
MENSTRUAL  HISTORY :          
 
MARITAL HISTORY  :                                                                                   
 
OBSTETRIC HISTORY: 
 
 
PAST HISTORY: 
 
GENERAL  EXAMINATION: 
HT:                        WT:                        TEMP:                        PR:                             BP: 
PALLOR:                                            PEDAL EDEMA: 
CVS:                                               RS: 
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P/A:                                                                                                
S/E: 
P/V: 
INVESTIGATIONS 
- Haemoglobin level 
 
- Blood grouping and typing 
 
- Oral glucose challenge test 
 
- HIV, VDRL HBs Ag 
 
- Urine for Albumin, Sugar and deposits 
 
- Obstetric Scan 
 
        -    Pre treatment AFI  
     -post treatment  AFI 
   -  Duration of  Hydration therapy  
        -   NST  
        -   Doppler study of UA/MCA: 
        -  Delivery at               Weeks GA              Date                  Time 
Mode of Delivery: Natural/outlet forceps/LSCS 
Indication for LSCS: Foetal distress/others 
BABY 
 : APGAR        1min         5Min 
 : Admission to NICU:               Yes/No 
 :  Reason for Admission:       Observation/MAS/Foetal distress 
:  Condition on discharge 
 :  Maternal Complications 
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ABBREVIATIONS 
 
AF =  Amniotic Fluid 
AFV = Amniotic Fluid Volume 
AFI = Amniotic Fluid Index  
FHR = Fetal Heart Rate 
LSCS = Lower Segment Caesarian Section 
PPROM = Preterm Premature rupture of membranes 
CTG = Cordio Toco Graph 
NICU = Neonatal Intensive Care Unit 
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PATIENT CONSENT FORM 
STUDY TITLE: ‘‘A PROSPECTIVE STUDY OF INTRAVENOUS 
HYDRATION THERAPY IN CASES OF 
OLIGOHYDRAMNIOS IN THIRD TRIMESTER AND 
ITS EFFECTS ON PERINATAL OUTCOME”  
STUDY CENTRE:  Government RSRM lying in hospital, Chennai. 
PARTCIPANT NAME:                                   AGE:         I.D.NO: 
I confirm that I have understood the purpose of the above study. I have the opportunity to ask the 
question and all my questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to withdraw at any 
time without giving any reason, without my legal rights being affected. 
I understand that investigator, the institution, regulatory authorities and the ethics committee will 
not need my permission to look at my health records both in respect to the current study and 
further research that may be conducted in relation to it, even if I withdraw from the study. I 
understand that my identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any data or results 
that arise from the study. 
I hereby consent to, undergo complete physical examination, and diagnostic tests including 
haematological, and ultra-sonogram examinations for me. 
I hereby consent to participate in this study on ‘‘A PROSPECTIVE STUDY OF 
INTRAVENOUS HYDRATION THERAPY IN CASES OF 
OLIGOHYDRAMNIOS IN THIRD TRIMESTER AND ITS EFFECTS ON 
PERINATAL OUTCOME” 
 
Place:                                      Signature of the Patient: 
Date:                                      Address: 
Signature of the witness:                                   Signature of Investigator: 
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  /     .............................................................................................................................. 
……………………………………………………………………………………………………… 
……………………………………………………………………………………………………… 
……………………………………………………………………………………………………… 
……………………………………………………………………………………………………… 
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Hydration Therapy)                    .      
                                      
                                  . 
 
 
 
         
     : 
    : 
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                    .   .   .   . 
                                      
                                          
  . 
                                        
          . 
 28                                     
                               (Intravenous Hydration 
Therapy)            . 
                                    
                                         
                                 . 
                                    
                                 (Ringer Lactate) 
                                          
                                    
                                  
           .  
                                          
                               ,        
    . 
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1 Sathya 19 2880 Primi 35 5.00 7.00 R N Clear 36.5 Normal 2.90 5 7 − −
2 Gowri 21 2911 Primi 35 5.00 6.80 R N Clear 36.3 Normal 2.90 6 7 − −
3 Anjali 23 3074 Multi 36 4.80 7.30 R N Clear 37 1 LSCS FD 2.80 6 7 ⁺ Observation Good −
4 Dhanam 22 3175 Primi 35 5.00 7.20 R N Clear 37 2 Outlet 2.70 7 9 −
5 Deepa 21 3235 Primi 36 4.80 8.00 R N Clear 37 1 Normal 2.80 7 8 −
6 Saranya 24 3294 Multi 37 4.70 7.00 NR N Thin MSAF 38 1 LSCS FD 3.10 5 7 ⁺ Observation Good −
7 Vanitha 19 3382 Primi 36 4.60 6.80 NR N Clear 37 1 LSCS FD 2.60 7 9 −
8 Geetha 29 3399 Multi 35 5.00 6.90 R N Clear 37 2 LSCS FD 2.70 5 7 ⁺ Observation Good −
9 Meena 21 3485 Primi 35 5.00 7.30 R N Clear 37 2 Normal 2.30 7 8 −
10 Kavitha 23 3499 Multi 36 4.80 6.80 R N Clear 37 2 LSCS FD 2.30 5 7 ⁺ Observation Good −
11 Deepa 17 3502 Primi 34 5.00 7.00 R N Clear 36.5 2.5 Normal 2.70 4 5 ⁺ RI Good −
12 Tamilselvi 23 3511 Primi 36 5.00 6.00 NR Ab Thin MSAF 37 1 LSCS FD 2.90 6 7 −
13 Keerthana 23 3527 Primi 35 5.00 6.90 R N Clear 37 1 LSCS Others 2.40 7 9 −
14 Kavitha 23 3572 Primi 36 4.00 6.80 R N Thin MSAF 37 1 LSCS FD 2.80 5 7 ⁺ Observation Good −
15 Dhanalakshmi 22 3579 Primi 35 5.00 7.00 R N Clear 37 1 Normal 2.70 6 9 −
16 Sharmila 24 3598 Multi 36 4.90 6.50 R N Moderate MSAF 37 1 LSCS FD 2.40 6 6 ⁺ RD −
17 Vasanthi 18 3603 Primi 36 5.00 6.50 R N Clear 37 1 Normal 2.40 7 8 −
18 Chithra 21 3604 Primi 36 4.80 6.80 R N Thin MSAF 37 1 Outlet 2.40 7 8 −
19 Hema 23 3631 Multi 35 5.00 6.80 R N Clear 37 2 Normal 2.37 7 8 −
20 Kalpana 24 3666 Multi 36 4.50 6.30 R N Clear 37 1 LSCS FD 2.40 7 9 −
21 Devi 26 3669 Multi 33 5.00 6.80 R N Clear 36.3 3.3 Normal 2.30 7 7 −
22 Subha 28 3680 Multi 36 5.00 6.80 R N Clear 37 1 Normal 2.60 7 9 −
23 Sandhiya 18 3908 Primi 35 5.00 6.80 R N Thin MSAF 36.5 1.5 Outlet 2.60 7 9 −
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24 Nandhini 25 3942 Multi 34 5.00 7.00 R N Clear 36.6 2.6 Normal 2.40 7 8 −
25 Kasthuri 26 3962 Multi 37 5.00 7.00 R N Clear 37 1 LSCS Others 3.10 7 9 −
26 Lela 27 3969 Multi 35 5.00 7.10 R N Clear 37 2 LSCS FD 2.60 6 7 ⁺ Observation −
27 Prema 22 4101 Primi 36 4.80 7.10 R N Clear 37 1 LSCS Others 2.40 6 8 −
28 Sudha 23 4192 Multi 35 5.00 6.80 R N Clear 37 2 Normal 2.40 6 7 −
29 Sri Devi 23 4280 Multi 35 5.00 6.90 R N Clear 37 2 Normal 2.30 7 8 −
30 Nadhiya 23 4282 Multi 36 4.60 7.00 R N Clear 37 1 LSCS Others 2.40 7 8 −
31 Shanthi 255 4320 Multi 37 5.00 7.20 R N Clear 38 1 LSCS Others 2.90 7 9 −
32 Suganthi 36 4410 Multi 35 5.00 6.90 R N Clear 37 2 Normal 3.20 7 9 −
33 Parimala 23 4442 Multi 35 5.00 6.80 R N Clear 37 2 Normal 2.40 7 9 −
34 Ranjani 22 4458 Primi 35 5.00 6.90 R N Clear 37 2.1 LSCS Others 2.60 7 8 −
35 Karthika 21 4469 Primi 36 5.00 6.50 NR Ab Thin MSAF 36.6 0.6 LSCS FI 2.60 4 5 ⁺ RD Died (Sepsis) −
36 Meena 23 4498 Multi 36 5.00 6.50 R N Clear 37 1 LSCS Others 2.75 6 7 −
37 Sarasu 23 4565 Multi 35 5.00 6.80 R N Clear 37 1 Normal 2.40 7 8 −
38 Sathya 22 4624 Primi 36 4.80 6.00 NR N Clear 37 1 LSCS FD 2.60 7 8 ⁺ Observation Good −
39 Janaki 18 4698 Primi 36 5.00 6.80 R N Clear 347 1 Outlet 2.75 7 8 −
40 Gomathi 26 4786 Multi 35 5.00 6.36 R N Clear 37 2 Normal 2.40 7 8 −
41 Geetha 33 4855 Multi 35 5.00 6.80 R N Clear 37 2 Normal 2.40 7 9 −
42 Rashiya 25 4901 Multi 35 5.00 6.30 R N Clear 37 2 Normal 2.40 7 8 −
43 Parveen 24 4914 Multi 35 5.00 6.80 R N Thin MSAF 37 2 Normal 2.30 6 7 −
44 Bharati 22 4927 Primi 35 4.50 6.80 R N Clear 36.6 2 Outlet 2.30 7 8 −
45 Salma 23 4932 Primi 36 4.60 6.80 R N Clear 37 1 Normal 2.75 6 9 −
46 Monika 19 4946 Primi 36 4.80 6.80 R N Clear 37 1 Normal 2.90 7 9 −
47 Divya 24 4950 Multi 37 5.00 6.80 R N Clear 38 1 LSCS FD 3.10 6 9 ⁺ Observation Good −
48 Jeevitha 24 4956 Multi 35 5.00 6.80 R N Clear 37 2 Normal 2.40 7 8 −
49 Manju 23 4988 Primi 36 4.90 7.00 R N Thin MSAF 37 1 Outlet 2.80 7 8 −
50 Muthulakshmi 19 4999 Primi 35 5.00 6.90 R N Clear 37 2 Outlet 2.40 6 7 −
51 Kuppammal 24 5004 Multi 35 5.00 6.80 R N Clear 37 2 Normal 2.90 6 7 −
52 Jerina 23 5119 Primi 36 5.00 6.80 R N Clear 37 1 LSCS FD 2.90 7 9 −
53 Bakyalakshmi 19 5128 Primi 36 5.00 6.80 R N Clear 37 1 LSCS FD 2.80 6 7 ⁺ Observation −
54 Anitha 24 5267 Multi 35 5.00 6.80 R N Clear 37 2 Normal 2.40 7 8 −
55 Eswari 23 5233 Primi 36 5.00 6.80 R N Clear 37 1 Outlet 2.70 7 8 −
56 Malini 26 5299 Multi 35 5.00 7.00 R N Clear 37 2 Normal 2.40 6 7 −
57 Kaliammal 19 5302 Primi 36 5.00 7.00 R N Clear 37 1 LSCS Others 2.70 7 8 −
58 Nirosha 25 5354 Multi 35 5.00 7.10 R N Clear 37 2 Normal 2.60 6 7 −
59 Gayathri 24 5452 Primi 36 5.00 7.00 R N Clear 37 1 LSCS Others 2.90 7 9 −
60 Santhiya 23 5495 Primi 36 5.00 7.00 R N Clear 37 1 LSCS Others 2.90 7 9 −
61 Vanishree 22 5527 Primi 36 5.00 7.00 R N Clear 37 1 LSCS Others 2.40 7 8 −
62 Rukshana 18 5544 Multi 36 6.00 6.80 R N Thin MSAF 37 1 LSCS 2.80 7 8 −
63 Rosi 24 5587 Multi 34 5.00 6.80 NR N Clear 36 2 Outlet 2.80 6 7 −
64 Mythili 23 5659 Primi 35 5.00 7.30 R N Clear 37 2 Normal 2.40 6 7 −
65 Indira 22 5662 Primi 35 5.00 7.20 R N Clear 37 2 Normal 2.40 6 7 −
66 Shamili 18 5697 Primi 36 5.00 7.00 R N Clear 37 1 LSCS Others 2.70 6 9 −
67 Ajimunisha 23 5724 Primi 36 5.00 8.00 R N Clear 37 1 Outlet 2.90 7 9 −
68 Raji 22 5736 Primi 35 5.00 7.30 R N Clear 37 2 Normal 2.40 7 8 −
69 Aruna 23 5766 Primi 36 5.00 7.20 R N Clear 37 1 LSCS Others 2.80 7 9 −
70 Ramani 23 5798 Primi 36 5.00 7.80 R N Thin MSAF 37 1 Outlet 2.90 6 7 ⁺ Observation Good −
71 Sudha 24 5802 Multi 35 5.00 7.10 R N Clear 37 1 Normal 2.30 6 7 −
72 Suseela 23 5816 Primi 36 5.00 7.30 R N Clear 37 1 Normal 2.30 6 7 −
73 Jothika 24 5841 Primi 34 5.00 7.40 R N Clear 36.2 2.2 Outlet 1.90 6 7 ⁺ SGA/LBW Good −
74 Monika 25 5918 Multi 35 5.00 7.00 R N Clear 37 2 Normal 2.60 6 7 −
75 Katheeja 24 5997 Multi 37 5.00 7.00 R N Clear 38 1 LSCS FI 3.10 7 9 −
76 Radha 23 6012 Primi 35 4.50 6.80 R N Clear 37 2 LSCS FD 2.40 6 7 ⁺ Observation Good −
77 Maha 26 6098 Multi 36 6.90 R N Clear 37 2 LSCS Others 2.30 7 8 −
78 Samanthi 25 6112 Multi 35 5.00 6.90 R N Clear 37 2 LSCS Others 2.30 7 8 −
79 Vanitha 25 6127 Multi 36 4.50 6.50 R N Thin MSAF 37 1 LSCS FD 2.80 7 9 −
80 Shanthi 25 6186 Multi 35 4.80 6.50 R N Clear 36.3 1.3 Normal 1.80 6 7 ⁺ SGA/LBW Good −
81 Sunitha 25 6212 Multi 36 4.80 7.00 R N Clear 37 1 LSCS FI 2.70 7 9 −
82 Priya 24 6218 Multi 35 5.00 6.80 R N Clear 37 2 Normal 2.40 7 8 −
83 Rejina 32 6267 Multi 35 4.80 6.80 NR N Clear 37 2 LSCS FD 2.30 7 8 −
84 Revathi 23 6292 Primi 36 5.00 7.00 R N Clear 37 1 LSCS Others 2.60 6 9 −
85 Sarala 24 6304 Multi 34 5.00 6.90 R N Clear 36.3 2.3 Normal 1.80 7 8 ⁺ SGA/LBW Good −
86 Malathi 23 6312 Primi 35 4.60 6.90 R N Clear 37 2 LSCS FI 2.40 7 8 −
87 Pnitha 33 6327 Multi 36 5.00 6.80 R N Moderate MSAF 37 1 LSCS FD 2.80 6 8 ⁺ Observation good −
88 Chithra 23 6334 Primi 35 5.00 8.00 R N Clear 37 2 Normal 2.30 6 7 −
89 Jothi 22 6342 Primi 36 5.00 7.20 R N Thin MSAF 37 1 Outlet 2.70 6 9 −
90 Devi 26 6410 Multi 35 5.00 7.00 R N Clear 37 2 Normal 2.75 6 9 −
91 Ranjitha 25 6421 Primi 36 5.00 7.20 R N Clear 37 1 LSCS FD 2.40 7 8 −
92 Rasul 26 6482 Multi 36 4.80 6.80 R N Thin MSAF 37 1 LSCS FD 2.40 7 8 ⁺ Observation Good −
93 Shakila 32 6543 Multi 35 5.00 6.80 R N Clear 36.3 1.3 Normal 1.95 6 7 ⁺ SGA/LBW Good −
94 Shabana 24 6633 Multi 68 5.00 6.80 R N Clear 36.6 1.6 Outlet 3.00 6 8 −
95 Indra 25 6688 Multi 35 5.00 6.80 R N Clear 37 2 Normal 2.30 7 8 −
96 Priya 25 6714 Multi 35 4.80 6.80 R N Clear 37 2 Normal 2.30 7 8 −
97 Asha 26 6728 Primi 36 5.00 6.80 R N Clear 37 1 LSCS 2.70 7 9 −
98 Divya 25 6734 Multi 35 4.80 6.80 R N Clear 37 2 Normal 2.40 7 8 −
99 Raji 24 6741 Multi 35 4.80 6.70 R N Clear 37 2 Normal 2.40 7 8 −
100 Sudha 25 6948 Primi 36 5.00 6.90 R N Clear 37 1 Normal 2.60 7 9 −
101 Amudha 23 7009 Primi 36 5.00 6.70 NR Ab Moderate MSAF 37 1 LSCS FD 2.40 3 4 ⁺ MAS(Died) −
102 Vasanthi 22 7111 Primi 35 5.00 7.20 R N Clear 37 2 Normal 2.45 6 7 −
103 Alen Mary 21 7128 Primi 36 4.80 6.80 NR N Thin MSAF 37 2 LSCS FD 2.40 5 7 ⁺ Observation Good −
104 Gulsar Bee 22 7214 Primi 36 5.00 7.00 R N Clear 37 1 Normal 2.30 6 7 −
105 Kuman 22 7216 Primi 36 5.00 7.00 R N Clear 37 1 LSCS Others 2.40 7 9 −
106 Sathya 34 7288 Multi 37 5.00 7.10 R N Clear 38 1 LSCS FI 3.10 7 8 −
107 Latha 22 7307 Primi 36 4.80 7.00 R N Clear 37 1 Normal 2.45 7 9 −
108 Gomathi 23 7328 Primi 36 5.00 7.00 R N Clear 37 1 LSCS FI 2.20 6 7 −
109 Suguna 24 7356 Multi 35 5.00 7.20 R N Clear 37 2 Normal 2.30 6 8 −
110 Komala 32 7384 Multi 35 5.00 6.40 NR N Clear 36 1 Normal 1.80 6 7 ⁺ SGA/Observation Good −
111 Anbuselvi 24 7401 Multi 36 5.00 7.20 NR N Thin MSAF 37 1 Outlet 2.30 5 7 ⁺ Observation Good −
112 Poornima 27 7418 Multi 36 5.00 6.70 R N Clear 37 1 LSCS FI 2.40 6 8 −
113 Vanitha 28 7427 Multi 36 4.50 6.50 R N Clear 37 1 LSCS FI 2.40 6 7 −
114 Delli Rani 28 7432 Multi 35 5.00 7.00 R N Clear 37 2 Normal 2.30 6 7 −
115 Samundi 23 7440 Primi 36 5.00 6.80 NR N Clear 37 1 LSCS FD 2.40 5 7 ⁺ Observation Good −
116 Baby 22 7492 Primi 5 5.80 7.30 R N Clear 39.1 0.1 Outlet 3.50 7 9 −
117 Aswathi 24 7517 Multi 37 4.90 6.30 R N Clear 37.3 0.3 LSCS Others 3.10 7 9 −
118 Renuka 24 7528 Multi 35 5.00 6.40 R N Clear 36.5 1.5 Normal 2.40 7 8 −
119 Beula 23 7540 Primi 366 5.00 6.40 R N Clear 37 1 LSCS FI 2.30 7 8 −
120 subha 23 7613 Primi 36 5.00 6.70 R N Clear 37 1 LSCS Others 2.40 7 9 −
121 Ameena 24 7700 Multi 35 5.00 6.20 R N Clear 37 2 Normal 2.40 7 8 −
122 Mubina 23 7812 Primi 36 4.90 6.90 R N Thin MSAF 37 1 Outlet 2.30 7 8 −
123 Divya 23 7918 Primi 36 5.00 7.10 R N Clear 37 1 Normal 2.40 7 8 −
124 Valarmathi 23 7984 Primi 33 5.00 6.00 NR Ab Thin MSAF 35 2 LSCS FI 1.70 6 7 ⁺ Observation Good −
125 Fatima 24 8004 Multi 37 5.00 6.30 R N Clear 38 1 LSCS FI 3.10 6 9 ⁺ −
126 Ambiga 25 8017 Multi 35 5.00 6.90 R N Clear 37 2 Normal 2.10 6 7 −
127 Gayathri 24 8119 Primi 36 5.00 6.80 R N Clear 37 1 Outlet 3.00 7 9 −
128 Radhika 24 8127 Primi 35 5.00 6.80 R N Clear 36.5 1.5 LSCS FI 1.90 5 7 ⁺ Observation Good −
129 Nadhiya 23 8131 Primi 36 5.00 7.20 R N Clear 37 1 Normal 2.40 7 9 −
130 Sharmila 22 8204 Primi 37 5.00 6.80 R N Clear 37.3 0.3 Normal 3.05 7 9 −
131 Sangeetha 21 8212 Primi 37 4.80 6.30 R N Clear 37.02 0.2 Normal 3.02 7 9 −
132 Vijaya 21 8221 Primi 37 5.00 6.90 R N Clear 37.1 0.1 Outlet 3.10 7 9 −
133 Kalaivani 21 8294 Primi 37 4.50 7.00 R N Clear 37.3 0.3 Normal 3.10 7 9 −
134 sumathi 21 8304 Primi 37 5.00 6.90 R N Thin MSAF 37.3 0.3 Outlet 3.10 7 8 ⁺ Observation Good −
135 Rihana 21 8327 Primi 37 4.80 6.80 R N Clear 37.3 0.3 Normal 3.00 7 8 −
136 Uma 21 8336 Primi 37 5.00 6.30 R N Clear 37.2 0.2 LSCS FI 2.90 6 7 −
137 Lilli 22 8415 Primi 37 5.00 6.20 R N Clear 37.1 0.1 Normal 2.90 7 8 −
138 Nalini 26 8487 Multi 34 5.00 6.37 R N Clear 36 2 Normal 2.20 6 7 −
139 Gomathi 23 8532 Primi 37 5.00 6.60 R N Thin MSAF 37.02 0.02 Outlet 3.00 7 8 −
140 Parvathi 26 8577 Multi 37 5.00 5.80 R N Clear 37.2 0.2 LSCS Others 3.00 7 8 −
141 Jothi 25 8618 Multi 37 5.00 6.00 R N Clear 37.3 0.3 LSCS FI 3.00 7 8 −
142 Jansirani 23 8636 Primi 37 5.00 6.20 R N Thin MSAF 37.3 0.3 Outlet 3.00 7 8 −
143 Lawanya 24 8673 Multi 37 5.00 6.80 R N Clear 37.2 0.2 LSCS Others 2.90 6 8 −
144 Tamilarasi 23 8714 Primi 37 5.00 7.00 R N Clear 37.2 0.2 LSCS FI 3.00 7 9 −
145 Devi 24 8745 Multi 37 5.00 6.30 R N Clear 37.2 0.2 LSCS 3.30 7 9 −
146 Shyamala 22 8797 Primi 37 5.00 6.70 R N Clear 37.5 0.5 LSCS FI 3.00 7 9 −
147 Shakira 22 8838 Primi 38 5.00 6.70 NR N Clear 38 0 LSCS FI 3.40 7 9 −
148 Deivanai 22 8902 Primi 37 5.00 6.80 R N Clear 37.3 0.3 LSCS FI 3.10 7 9 −
149 Salma 22 8917 Primi 37 5.00 6.90 R N Clear 37.2 0.2 LSCS Others 3.01 7 8 −
150 Farida 22 8999 Primi 37 5.00 7.00 R N Clear 37.2 0.2 Normal 3.10 7 8 −
NST = Non Stress test
R = Reactive
NR = Non-reactive
N = Normal
Ab = Abnormal
MSAF = Meconium Stained Amniotic fluid
FD = Fetal Distress
FI = Failed Induction
RD = Respiratory Distress
SGA = Small For Gestational Age
LBW = Low Birth Weight
NICU = Neonatal Intensive Care Unit
1 Kavitha 19 1036 Primi 36.0 8.0 NR ThinMSAF LSCS 2.80 6 7 ⁻
2 Lakshmi 22 1039 Primi 38.0 8.3 R Clear LSCS 3.10 6 9 ⁻
3 Samsath Begum 22 1040 Multi 37.0 7.4 R Clear Normal 2.80 6 8 ⁻
4 Ruksana 21 1043 Multi 37.0 9.6 R Clear Normal 2.80 7 8 ⁻
5 Ramya 22 1045 Multi 37.0 9.0 R Clear Normal 2.80 7 9 ⁻
6 Mala 25 1178 Multi 37.0 8.0 R Clear Normal 2.80 6 7 ⁻
7 Rasma 22 1132 Primi 39.0 7.4 R Clear Outlet 3.50 7 8 ⁻
8 Yogalakshmi 21 1371 Primi 374.0 1.3 R Clear Outlet 2.80 7 8 ⁻
9 Deepalakshmi 25 1231 Multi 37.0 9.3 R Clear Normal 2.80 7 9 ⁻
10 Kaveri 29 1230 Multi 37.0 9.4 R Clear Outlet 2.80 7 8 ⁻
11 Karthika 21 1243 Primi 37.0 8.7 R Clear LSCS 3.00 7 9 ⁻
12 Priyanka 27 1248 Multi 37.0 8.0 R Clear LSCS 2.80 6 7 ⁻
13 Kavitha 26 1252 Multi 37.0 8.0 R Clear LSCS 2.80 7 8 ⁻
14 Gowthami 28 1269 Multi 37.0 8.0 R Clear Normal 3.00 7 9 ⁻
15 Suganya 25 1273 Primi 37.0 7.4 R Clear Outlet 3.00 7 9 ⁻
16 Yuvarani 16 1284 Multi 37.0 8.8 R Clear Normal 3.00 7 9 ⁻
17 Sumithra 23 1300 Primi 37.0 8.7 R Clear Normal 3.00 7 9 ⁻
18 Rajathi 25 1323 Multi 36.6 8.8 R Clear LSCS 1.90 6 7 ⁺ SGA/LBW Good ⁻
19 Nilofar 22 1418 Multi 36.6 9.3 R Clear Normal 3.00 6 7 ⁻
20 Sarata 24 1490 Multi 36.6 8.4 R Clear Normal 3.00 6 9 ⁻
21 Devi 29 1512 Multi 36.6 8.0 R Clear Normal 2.40 7 8 ⁻
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22 Priya 21 1514 Multi 36.6 9.2 R Clear Normal 2.30 7 8 ⁻
23 Dilshath 22 1610 Multi 36.6 9.4 R Clear Normal 3.00 6 9 ⁻
24 Manjula 18 1612 Primi 37.0 8.7 R Clear Outlet 3.00 7 8 ⁻
25 Mohana 23 1800 Multi 37.0 9.3 R Clear Normal 2.60 7 8 ⁻
26 Kanchana 25 1892 Multi 37.0 9.4 R Clear Normal 2.80 7 9 ⁻
27 Sarala 20 1901 Primi 36.2 9.0 R Clear Outlet 2.70 6 7 ⁻
28 Sangeetha 21 1912 Multi 36.1 8.8 R Clear Normal 2.70 7 8 ⁻
29 Mahalalkshmi 24 1923 Multi 37.0 7.9 R Clear Normal 2.80 7 9 ⁻
30 Akila 21 1936 Primi 37.0 9.0 R Clear Outlet 2.60 6 7 ⁻
31 Lkamatchi 27 1937 Multi 36.5 8.9 R Clear Normal 2.40 7 8 ⁻
32 Radhika 21 1939 Primi 36.6 7.7 R ThinMSAF Normal 2.70 6 7 ⁻
33 Sudha 27 1978 Multi 37.0 9.3 R Clear Normal 2.75 7 9 ⁻
34 Selvi 19 1987 Primi 37.0 9.3 R Clear LSCS 2.75 6 9 FD ⁻
35 Jothi 25 1999 Multi 27.0 9.3 R Clear Normal 2.75 7 8 ⁻
36 Noori 21 2004 Multi 37.0 10.4 R Clear Normal 2.75 7 8 ⁻
37 Lakshmi 21 2010 Primi 37.0 11.0 R Clear Outlet 2.70 7 8 ⁻
38 Josephin 32 2018 Multi 38.0 12.3 R Clear LSCS 3.50 7 9 ⁻
39 Nithya 21 2104 Primi 37.0 11.7 NR ThinMSAF LSCS 2.80 6 9 ⁻
40 Shyamala 29 2110 Multi 36.6 13.0 R Clear Normal 2.50 7 8 ⁻
41 Mibina 21 2121 Primi 35.5 10.2 R Clear Outlet 1.80 6 7 ⁻
42 Meena 22 2124 Multi 36.6 17.4 R Clear Normal 2.50 7 9 ⁻
43 Sridevi 24 2126 Primi 37.0 14.0 R Clear LSCS 3.40 6 9 FD ⁻
44 Geetha 24 2128 Primi 37.1 10.0 NR ThinMSAF LSCS 2.90 6 9 FD ⁺ Observation Good ⁻
45 Rajeswari 28 2131 Multi 37.1 8.3 R Clear Normal 2.85 7 8 ⁻
46 Priya 27 2142 Multi 34.3 8.7 R Clear Normal 2.25 6 7 ⁺ preterm Good ⁻
47 Madavi 20 2168 Primi 37.1 9.0 R Clear Normal 2.65 7 9 ⁻
48 Kanchana 24 2202 Primi 37.0 9.0 NR ThinMSAF LSCS 1.80 6 7 FD ⁺ SGA/LBW Good ⁻
49 Saranya 21 2212 Primi 35.9 9.3 R Clear LSCS 2.60 5 6 FD ⁺ preterm Good ⁻
50 Ramya 24 2224 Multi 35.5 8.0 R Clear LSCS 2.70 7 9 ⁻
51 Gomathi 22 2248 Primi 37.0 7.4 R Clear Normal 2.75 ⁻
52 Maha 21 2253 Primi 37.0 7.8 R ThinMSAF Outlet 3.30 ⁻
53 Rajeswari 21 2256 Primi 37.0 7.7 R Clear LSCS 3.20 7 9 FI ⁻
54 Kanmani 20 2274 Primi 36.6 7.8 R Clear LSCS 3.30 7 9 FI ⁻
55 Anandhi 21 2292 Primi 37.0 9.3 R Clear LSCS 3.40 7 9 Others ⁻
56 Bagavathi 21 2301 Primi 37.0 9.3 R Clear Outlet 3.40 7 8 ⁻
57 Arul Mozhi 25 2334 Multi 37.0 12.0 R Clear Outlet 3.40 7 9 ⁻
58 Jothi 20 2314 Primi 37.0 10.3 R Clear Outlet 3.40 7 8 ⁻
59 Jen itha 20 2321 Primi 37.0 11.8 R Clear Normal 3.20 7 9 ⁻
60 Thenmozhi 25 2334 Multi 37.0 12.0 R Clear Outlet 3.40 7 9 ⁻
61 sudha Rani 25 2336 Multi 37.0 8.3 R Clear LSCS 3.20 7 9 FI ⁻
62 Revathi 22 2338 Primi 36.6 8.4 R Clear Normal 2.70 7 8 ⁻
63 Meenatchi 25 2342 Multi 36.5 8.5 R Clear Normal 2.90 7 8 ⁻
64 Divya 22 2510 Primi 37.0 8.6 R Clear Normal 2.90 7 9 ⁻
65 Ramish Bee 22 2612 Primi 37.0 9.3 R Clear Normal 2.90 7 8 ⁻
66 Suhasini 22 2688 Primi 37.1 10.1 R Clear LSCS 3.00 7 9 FI ⁻
67 Nirmala 20 2914 Primi 37.2 9.8 R Clear LSCS 3.00 7 9 FI ⁻
68 Shanthi 23 3003 Multi 33.5 8.3 R Clear Normal 1.80 7 8 ⁺ preterm Observation Good ⁻
69 Kanchana 31 3121 Multi 37.0 9.0 R Clear LSCS 3.00 7 8 ⁻
70 Nandhini 22 3140 Primi 37.5 8.7 R Clear Outlet 3.50 7 8 ⁻
71 Booma Devi 21 3208 Primi 37.5 8.8 R Clear Outlet 3.50 7 9 ⁻
72 Samanthi 29 3400 Multi 37.2 7.8 R Clear LSCS 3.50 7 8 FI ⁻
73 Parveen 22 3432 Primi 37.0 8.9 R Clear Normal 3.20 7 9 ⁻
74 Abibunisa 22 3488 Primi 37.0 9.2 R Clear Normal 3.10 7 8 ⁻
75 Reena 20 3565 Primi 37.0 8.7 NR Clear LSCS 3.10 6 6 FD ⁺  Observation Good ⁻
76 Yasmin 25 3590 Multi 37.0 8.3 R ThinMSAF Outlet 3.00 7 9 ⁻
77 Sangeetha 19 3595 Primi 37.0 8.4 R ThinMSAF Outlet 2.80 7 9 ⁻
78 Samshath 23 3674 Multi 37.0 8.6 R Clear Normal 3.20 7 8 ⁻
79 Mehala 21 3679 Primi 36.5 8.5 R Clear Outlet 2.40 7 8 ⁻
80 Deepa 21 3712 Primi 36.3 8.4 R Clear Outlet 2.50 7 8 ⁻
81 Bharati 24 3866 Multi 36.2 9.2 R Clear Normal 2.50 7 8 ⁻
82 Mobeen 21 3912 Multi 36.1 9.3 R Clear LSCS 2.50 7 8 ⁻
83 Sathya 22 3920 Multi 36.6 9.0 R Clear Normal 2.70 7 9 ⁻
84 Suganya 21 3922 Primi 36.8 8.8 R Clear Normal 2.40 7 8 ⁻
85 Thoulath 22 3948 Multi 37.0 11.0 R Clear Normal 2.60 7 8 ⁻
86 Komala 21 3955 Primi 3.3.6 8.8 R Clear Normal 1.70 7 8 ⁻
87 Deepa 21 3968 Primi 37.1 8.7 R Clear LSCS 2.70 7 9 FD ⁺ preterm Observation Good ⁻
88 Geetha 20 3969 Primi 37.2 8.7 R Clear LSCS 3.50 7 9 ⁻
89 Sulaika Banu 22 3998 Primi 37.3 8.0 R Clear LSCS 3.60 6 7 FD ⁻
90 Priya 21 4002 Primi 37.0 8.3 R Clear Normal 2.50 7 9 ⁻
91 Deepa 32 4012 Multi 37.0 8.9 R Clear Normal 2.80 6 8 ⁻
92 Meena 20 4015 Primi 3.7 9.7 R Clear Normal 2.60 7 9 ⁻
93 Vanishree 21 4028 Primi 36.6 14.0 R Clear Outlet 2.50 7 8 ⁻
94 Jerina 21 4099 Multi 36.6 11.7 R Clear LSCS 2.40 7 8 ⁻
95 Anitha 18 4124 Primi 36.5 13.0 R Clear LSCS 2.50 6 7 FI ⁻
96 Kuppammal 21 4132 Primi 37.0 13.0 R Clear Normal 2.60 6 7 ⁻
97 Malimni 27 5001 Multi 37.5 9.3 R Clear Normal 3.00 7 9 ⁻
98 Nirosa 22 5007 Primi 33.0 14.0 R Clear Normal 2.30 6 7 ⁺ preterm Good ⁻
99 Vasanthi 19 5123 Primi 37.0 9.0 R Clear LSCS 2.80 7 9 FI ⁻
100 Gayathri 24 5148 Multi 37.0 9.4 R ThinMSAF Normal 2.60 7 9 ⁻
101 Indu 22 5208 Primi 34.0 13.2 R Clear Normal 2.00 6 7 ⁺ preterm Good ⁻
102 Poonghodi 24 5250 Multi 36.6 10.4 R Clear LSCS 2.40 7 8 ⁻
103 Indira 21 5256 Primi 32.0 11.0 R Clear Normal 1.60 6 7 ⁺ preterm/LBW Good ⁻
104 Satya 24 5341 Multi 37.6 8.4 R Clear LSCS 3.60 7 9 Others ⁻
105 Poonghodi 24 5444 Primi 37.6 9.0 R ThinMSAF Normal 2.90 7 9 ⁺  Observation Good ⁻
106 Indira 20 5528 Primi 37.0 8.3 R Clear LSCS 2.80 7 9 FI ⁻
107 Nagavalli 21 5612 Primi 32.0 14.0 R Clear Normal 1.40 6 7 ⁺ preterm /LBW Died (Sepsis) ⁻
108 Maheswari 23 5725 Primi 40.0 7.4 R ThinMSAF LSCS 3.60 7 9 FI ⁻
109 Renuka 22 6014 Primi 38.2 7.3 R Clear LSCS 3.20 6 7 FD ⁻
110 Jansi 19 6126 Primi 37.4 8.3 NR ThinMSAF LSCS 3.30 6 6 FD ⁺ MAS Died ⁻
111 Arul 27 6156 Multi 34.0 14.3 R Clear LSCS 2.00 6 7 Others ⁺ preterm Good ⁻
112 Vimala 27 6455 Multi 37.4 13.8 R Clear LSCS 3.00 7 9 FI ⁻
113 Rajalakshmi 22 6680 Primi 37.1 13.2 R Clear Outlet 21.80 7 9 ⁻
114 Rosy 22 6788 Primi 37.4 14.0 R Clear Normal 3.00 7 9 ⁻
115 Chithra 24 6825 Multi 37.2 11.6 R Clear LSCS 3.00 7 9 Others ⁻
116 Gandhimathi 24 6988 Multi 37.3 12.1 R Clear LSCS 3.00 7 8 Others ⁻
117 Ramani 23 7011 Multi 37.0 11.6 R Clear LSCS 2.80 7 8 Others ⁻
118 Sudha 21 7098 Primi 34.0 10.8 R Clear Normal 2.40 6 7 ⁺ preterm Good ⁻
119 Manjula 22 7135 Primi 37.0 10.7 R Clear Normal 3.10 7 9 ⁻
120 Jothika 20 7168 Primi 36.5 9.3 R Clear Normal 2.40 6 7 ⁻
121 Nithya 27 7233 Multi 36.4 9.8 R Clear LSCS 2.50 7 8 Others ⁻
122 Saraswathy 21 7348 Primi 37.0 11.4 R ThinMSAF Outlet 3.00 7 8 ⁺  Observation Good ⁻
123 Sameem 24 7400 Multi 36.3 11.2 R Clear LSCS 2.49 7 8 FD ⁻
124 Arokiamary 23 7412 Multi 36.6 11.4 R Clear LSCS 2.49 6 7 FD ⁻
125 Sureka 20 7428 Primi 36.3 12.7 R ThinMSAF LSCS 2.49 7 9 FI ⁻
126 Radha 25 7532 Multi 37.0 10.8 NR Clear Outlet 3.40 7 9 ⁻
127 Devi 23 7612 Primi 36.2 10.8 R Clear Outlet 2.50 7 8 ⁻
128 Sudha 23 7614 Primi 34.0 10.5 R Clear LSCS 2.00 7 9 FD ⁺ preterm/LBW Good ⁻
129 Katheja 22 7715 Primi 37.6 11.0 R Clear Normal 2.80 7 9 ⁻
130 Aruna 27 7718 Multi 37.6 11.2 R Clear LSCS 2.70 7 8 FI ⁻
131 EmiliDevi 23 7814 Primi 37.0 9.6 R Clear Normal 2.75 7 9 ⁻
132 Rajakumari 21 7847 Primi 37.3 8.0 R Clear Normal 2.70 7 8 ⁻
133 Sowmiya 27 7864 Multi 37.3 9.8 R Clear LSCS 2.65 7 8 FI ⁻
134 Geethalakshmi 24 7877 Multi 37.3 9.8 R ThinMSAF LSCS 2.70 7 9 FI ⁻
135 Seetha 29 7912 Multi 37.5 9.8 R Clear LSCS 2.60 7 8 ⁻
136 Anu 25 7918 Multi 37.6 15.2 R Clear LSCS 2.80 7 8 ⁻
137 Prema 24 7923 Primi 37.6 14.0 R Clear Normal 2.70 7 9 ⁻
138 Durga 21 7927 Primi 37.6 13.2 R Clear Normal 2.75 7 9 ⁻
139 Leela 20 7954 Primi 37.0 12.0 R Clear Normal 2.60 7 8 ⁻
140 Valarmathy 25 7955 Multi 37.0 11.2 NR ThinMCAS LSCS 2.70 7 8 ⁻
141 Ashadevi 22 7956 Primi 37.0 9.9 R Clear Normal 2.80 7 9 ⁻
142 Priya 21 7964 Primi 37.4 10.4 R Clear Normal 3.10 7 9 ⁻
143 Elakiya 22 7972 Primi 37.3 9.0 R Clear Normal 2.40 7 8 ⁻
144 Aswini 22 7974 Prime 36.6 9.8 R Clear Normal 2.30 7 8 ⁻
145 Vinitha 22 7976 Prime 37.5 10.0 R Clear Normal 3.10 7 8 ⁻
146 Manjula 22 7982 Multi 33.0 11.4 R Clear Normal 2.00 7 8 ⁻
147 Thangamani 20 7983 Prime 37.2 11.4 R Clear Normal 3.00 7 8 ⁻
148 Meena 21 7984 Prime 36.0 10.2 R Clear Normal 25.60 7 8 ⁻
149 Mala 22 Multi 40.0 8.3 R Clear Normal 3.40 7 8 ⁻
150 Kousalya 21 Prime 34.0 11.4 R Clear Normal 2.40 7 8 ⁺ pretern/LBW Good ⁻
NST = Non Stress test
R = Reactive
NR = Non-reactive
N = Normal
Ab = Abnormal
MSAF = Meconium Stained Amniotic fluid
FD = Fetal Distress
FI = Failed Induction
RD = Respiratory Distress
SGA = Small For Gestational Age
LBW = Low Birth Weight
NICU = Neonatal Intensive Care Unit
